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MULTISTAGE DELIVERY OF ACTIVE
AGENTS
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BACKGROUND
Technical Field
The present inventions relate generally to the field of
nanotechnology and, in particular, to compositions utilizing
micro and/or nanoparticles for delivery active agents, such
as therapeutic and imaging agents, and methods of making
and methods of using such compositions.
Description of Related Art
The past quarter century's progress in the fundamental
understanding of health and disease has not translated into
comparable advances in clinical medicine. Inadequacies in
the ability to administer therapeutic moieties so that they
will selectively reach desired targets with marginal or no
collateral damage has largely accounted for the discrepancy,
see, e.g., Langer, R. Nature 392, 5-10 (1998); and Duncan,
R. Nature Rev. Drug Discov. 2, 347-360 (2003).
Ideally, an active agent, such as a therapeutic or imaging
agent, should travel through vasculature, reach the intended
target at full concentration, then act selectively on diseased
cells and tissues only, without creating undesired side
effects. Unfortunately, even the best current therapies fail to
attain this ideal behavior by a wide margin.
Nano-scale and micro-scale drug delivery systems, also
known as ` nanovectors', are promising candidates for pro-
viding solutions to the problem of optimizing therapeutic
index for a treatment, i.e. maximizing efficacy, while reduc-
ing health-adverse side effects. Even modest amounts of
progress towards this goal have historically engendered
substantial benefits across multiple fields of medicine, with
the translatability from, for example, a subfield of oncology
to a field as distant as the treatment of infectious disease
being granted by the fact that the progresses had a single
common denominator in the underlying technological plat-
form. For example, liposomes, the first nanovector therapy
to reach health-care fruition over 10 years ago for treatment
of Kaposi's sarcoma, have also yielded advances in the
treatment of breast and ovarian cancers, as well as fungal
infections.
Today, many hundreds, if not thousands, of different
nanovector technology platforms have joined liposomes,
each with different properties, strengths, and weaknesses.
Various nanovector platforms include polymer-based plat-
2
forms, dendrimers, gold nano-shells, semiconductor nano-
crystals, fullerenes, biologically derived nano-constructs,
silicon- and silica-based nanosystems and superparamag-
netic nanoparticulates are described in the literature. sup.49-
5 75.
SUMMARY
In certain embodiments a composition is provided which
10 comprises at least one first stage particle that is a micro or
nanoparticle and that has (i) a body, (ii) at least one surface,
and (iii) at least one reservoir inside the body, such that the
reservoir contains at least one second stage particle that
comprises at least one active agent.
15 In certain embodiments a method is provided which
comprises administering to a subject a composition com-
prising: at least one first stage particle, that is a micro or
nanoparticle and that has (i) a body, (ii) at least one surface
and (iii) at least one reservoir inside the body, such that the
20 reservoir contains at least one second stage particle that
comprises at least one active agent.
In still another embodiment a method of making a mul-
tistage delivery system is provided which comprises (A)
providing at least one first stage particle, that is a micro or
25 nanoparticle and that has (i) a body, (ii) at least one surface
(iii) at least one reservoir inside the body; (B) providing at
least one second stage particle and (C) loading the at least
one second stage particle inside the reservoir of the first
stage particle. These and other embodiments, features and
30 advantages will be apparent with reference to the following
description and drawings
BRIEF DESCRIPTION OF THE DRAWINGS
35 FIG. 1 illustrates a multistage delivery vehicle, in accor-
dance with an embodiment of the invention. The first stage
particle contains inside second stage particles. The second
stage particles may comprise at least one active agent, such
as a therapeutic agent or an imaging agent. The first stage
40 particle also contains inside an additional agent, such as a
permeation enhancer or an additional active agent, which
may be an imaging agent or a therapeutic agent. Optionally,
the second stage particles contain third stage particles.
Targeting moieties, such as antibodies, aptamers or ligands,
45 attached to the surface of the first stage particle, facilitate
localization at the selected body site.
FIGS. 2A-213 illustrate the principle of operation of a
multistage delivery vehicle administered intravascularly, in
accordance with an embodiment. The first stage particle
50 localizes at the targeted vasculature location. Upon the
localization, the particle releases permeation enhancers that
generate a fenestration in the vasculature. Second stage
particles carry targeting moieties, such as antibodies. The
second stage particles may permeate through the fenestra-
55 tion and target specific cells that carry surface marker
antigens, using the antibodies.
FIG. 3, Panel A, depicts time dependence of amino and
carboxy modified quantum dots (q-dots) in APTES modified
"large pore" LP and "small pore" nanoporous silicon first
60 stage particle. FIG. 3, Panel B, demonstrates an effect of
second stage PEG-FITC-SWNT nanoparticles concentration
on their loading into nanoporous silicon first stage particles.
In Panels A and B, Y-axis reads mean fluorescence.
FIGS. 4A-4D demonstrate time dynamics of second stage
65 nanoparticles loading into nanoporous silicon first stage
particles. 4A for "large pore" (LP) oxidized silicon first stage
particles; 4B for LP APTES modified silicon first stage
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particles; 4C for "small pore" (SP) oxidized silicon first
stage particle; 4D for SP APTES modifies silicon first stage
particles. Y-axis reads mean fluorescence.
FIG. 5 demonstrates time dynamics of second stage
nanoparticles release from LP oxidized nanoporous silicon 5
first stage particles (Panel A) and LP APTES modified
nanoporous silicon first stage particles (Panel B). In Panel A
and Panel B, Y-axis reads released payload (%).
FIG. 6A, Panel A, presents the concentration effect of
loading carboxy modified quantum dots and FITC-conju-
gated single wall carbon nanotubes (SWNTs). Y axis in
Panel A reads mean fluorescence (%). FIG. 6A, Panel B,
demonstrates fluorescence quenching of Fluorescein Isoth-
iocyanate (FITC) conjugated Single Wall Carbon Nanotubes 15
(SWNT).
FIG. 6B relates to optimization of chemical condition for
loading of second stage particles into nanoporous silicon
particles. Nanoporous silicon particles were mixed with
second stage nanoparticles (Q-dots in FIG. 613, Panel C and 20
Panel D; PEG-FITC-SWNTs in Panel E and Panel F) in the
presence of increasing concentration of TRIS. High concen-
tration of TRIS helped in increasing the amount of Q-dots
loaded into the first stage silicon particles (Panel C and Panel
D). On the contrary, loading efficiency of PEG-FITC- 25
SWNTs reached its peak at 20 Mm TRIS and then decreased
at higher TRIS concentrations, Panel E and Panel F. Y axis
in Panels B-F reads mean fluorescence.
FIG. 7 demonstrates data for loading and release respec-
tively FITC conjugated with SWNT second stage particles 30
into LP nanoporous silicon first stage particles. Panel A
presents load columns, corresponding to the amount of
FITC-SWNT initially loaded in the nanoporous silicon first
stage particles after exposure to a FITC-SWNT solution 35
prior to washing. Wash columns in Panel A corresponds to
the amount of FITC-SWNT after washing the first stage
particles. The actual load of the FITC-SWNT in the first
stage particles is the amount of FITC-SWNT retained in the
first stage particles after washing, i.e., a difference between 40
the respective values in the load column and in the wash
column. Panel B shows data for release of FITC-SWNT
from the first stage particles over time. The total amount of
FITC-SWNT released from the first stage particles over
time, i.e., a sum of all the columns in Panel B, substantially 45
matches the difference between respective load and wash
columns in Panel A. Y axis in Panels A and B reads amount
of FITC-SWNTs (ng).
FIGS. 8A-B present data for lipid based second stage
particles loading into nanoporous silicon first stage particles. 50
In FIG. 8A, Panels A-C show data for cationic and neutral
liposomes loaded into I micron nanoporous silicon first
stage particles. Panel A shows confocal microscopy images
of neutral liposomes (left) and cationic liposomes (right).
Panels B and C present respectively FACS analysis and 55
Excel quantification of neutral and cationic liposome load-
ing into I micron nanoporous silicon first stage particles. Y
axis in Panel B reads particle number and Y axis in Panel C
reads green fluorescence (logarithmic values). In FIG. 813,
Panel D shows time dynamics of loading liposomes con- 60
taining Alexa 555 labeled SiRNA into 3.5 micron nanop-
orous oxidized silicon first stage particles. Y axis in Panel D
reads mean fluorescence. Panel E and Panel F present
fluorescent microscopy images visualizing fluorescence
associated with liposomes containing Alexa 555 labeled 65
SiRNA into 3.5 micron nanoporous silicon first stage par-
ticles.
_►,
FIGS. 9A-9D demonstrate Scanning Electron Microscopy
(SEM) images of "large pore" (LP) nanoporous silicon first
stage particles.
FIGS. 10A-10D demonstrate Scanning Electron Micros-
copy (SEM) images of "small pore" (SP) nanoporous silicon
first stage particles.
FIGS. 11A-11D demonstrate degradation of nanoporous
silicon particles measured using Z2 Coulter.RTM. Particle
Counter. Y axis in 11A and 11B reads number of particles.
Y axis in 11C and 11D reads volume of particles.
FIGS. 12A-B demonstrate degradation of nanoporous
silicon particles measured using Inductive Coupled
Plasma Atomic Emission Spectrometry. FIG. 12A, Panel
A, for LP oxidized silicon particles; Panel B for SP oxidized
silicon particles; FIG. 1213, Panel C, for LPAPTES modified
silicon particles. Panel D for SP APTES modified silicon
particles. Y axis in FIGS. 12A-12B reads concentration of
silicon (ng/mL).
FIG. 13 demonstrates biocompatability of nanoporous
silicon first stage particles by presenting bright field micros-
copy images of selected nanoporous silicon particles and
Human Umbilical Vein Endothelial Cells (HUVEC) cells. In
particular, Panel A demonstrates images for small pore
oxidized silicon nanoparticles; Panel B demonstrates images
for small pore APTES modified silicon nanoparticles; Panel
C demonstrates images for large pore oxidized silicon nano-
particles; Panel D demonstrates images for large pore
APTES modified silicon nanoparticles. In each Panel A-D,
from left to right: first image day 0 (2 hrs after particles
addition), second image day 1; third image day 2; fourth
image day 3.
FIGS. 14A-B demonstrate biocompatibility of nanop-
orous silicon particles by presenting data for Lactate Dehy-
drogenase (LDH) toxicity assay on HUVEC cells incubated
with nanoporous silicon nanoparticles. Y axis in Panels A-F
reads absorbance at 490 mu.
FIGS. 15A-B present data for MTT proliferation assay on
HUVEC cells incubated with nanoporous silicon nanopar-
ticles. Y axis in FIG. 15A, Panels A-13 and FIG. 1513, Panels
C-F reads absorbance at 570 mu.
FIGS. 16A-1-16C-3 present FACS 3D Profiles of
HUVEC cells incubated with Nanoporous Silicon Particles
and analyzed for their size and shape.
FIGS. 17A-17I present FACS 3D Profiles of HUVEC
cells incubated with Nanoporous Silicon First Stage Par-
ticles and stained with propidium iodide to study cell cycle.
FIGS. 18A-C present statistical analysis of different
phases of the cell cycle of cells exposed to nanoporous
silicon first stage particles. Y axis in FIG. 18A, Panels A-C,
FIG. 1813, Panels D-G, and FIG. 18C, Panels H-K reads %
of total cell population.
FIG. 19, Panels a and b, demonstrate SEM images of a
porous silicon particle. "Large pore" (LP, FIG. 19a) and
"small pore" (SP, Panel b) particle images showing (from
left to right) the back side, front side, a cross-section, a
closer view of the pores on the back side and of the pores in
the cross-section. The size and shape of the LP and SP
particles are the same, the size and structure of the pores are
significantly different.
FIG. 20 presents results of flow cytometric and fluores-
cence microscopy analysis of loading of fluorescently
labeled Q-dots and PEG-FITC-SWNTs into nanoporous
silicon particles. An increase in the amount of nanoparticles
in the loading solution resulted in an increase in the mean
fluorescence of silicon particles (.diamond-solid. LP
APTES+Carboxyl Q-dots LP oxidized+Amino Q-dots .box-
solid. SP APTES+Carboxyl Q-dots .tangle-solidup. SP oxi-
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dized+Amino Q-dots) measured by flow cytometry (Panels
A and B). Fluorescent microscopy (Panels C and D) con-
firmed that the fluorescence associated to first stage particle
was dimmer when the amount of nanoparticles used was
lower. Y axis in Panels A and B reads mean fluorescence.
FIGS. 21A-21H present time dependent loading and
releasing of second stage particles in nanoporous silicon first
stage particles. Four different types of nanoporous silicon
first stage particles (LP oxidized (A), LP APTES (B), SP
oxidized (C), and SP APTES (D) were loaded with different
second stage nanoparticles (Carboxyl q-dots, .box-solid.
Amino q-dots, tangle-solidup. PEG-FITC-SWNTs) and their
fluorescence measured by flow cytometry. Histograms in
21E-21H represent a percentage of second stage particles
released from the first stage silicon particles with the pas-
sage of time.
FIG. 22 presents confocal microscopy images demon-
strating concentrated loading of Q-dots in a highly porous
region of the back side of silicon particle. Panel a shows
confocal microscopy images reconstructed in a series of 3
dimensional projections showing a single porous silicon
particle rotated to display different vantage points. Panel b
shows computer generated 3 dimensional models illustrating
the rotation of the particle as shown in Panel a.
FIGS. 23A-23C illustrate simultaneous loading and
releasing of Q-dots and PEG-FITC-SWNTs second stage
particles in nanoporous silicon first stage particles. Flow
cytometry analysis showing background green and red fluo-
rescence of LP APTES particles (Unloaded; FIG. 23A, Panel
A and Panel B respectively) and the shifts of the fluores-
cence signals after the incubation with PEG-FITC-SWNTs
(+SWNTs), Q-dots (+Q-dots) and both (+Q-dots+SWNTs).
Flow cytometry analysis show that PEG-FITC-SWNTs load
rapidly and stabilize, while Q-dots gradually load before
reaching a plateau, see FIG. 23B, Panel C. The release
profiles of the Q-dots and PEG-FITC-SWNTs are both
unaltered by the presence of another type of nanoparticle
and are both sustained along time, FIG. 23 B, Panel D.
Confocal microscopy images show the localization of the
Q-dots (red) and PEG-FITC-SWNTs (green) in a single
porous silicon particle. FIG. 23C, Panel E, Panel F and Panel
G show bright field, green and red fluorescence respectively,
while Panel h shows overlay of the 3 channels are shown.
Yellow display showed co-localization of green and red
fluorescent signals. Y axis in FIG. 23 B, Panel D, reads mean
fluorescence; Y axis in Panel D reads released payload.
FIG. 24, Panels a-m, show fluorescent spectroscopy
images related to incubating nanoporous silicon particles
loaded with second stage particles with HUVEC cells for 1
h at 37 C. In FIG. 24, Panels a-d, the second stage particles
are Q-dots; in Panels e-h, the second stage particles are
PEG-FITC-SWNTs; in Panels j-m, the second stage par-
ticles are Q-dots and PEG-FITC-SWNTs. FIG. 24, Panels d,
h and m are bright field images showing the details of
particle morphology.
FIG. 25, Panels A-C, present computer models represent-
ing the three major physical, chemical and electrostatic
mechanisms responsible for loading and release of second
stage nanoparticles in first stage silicon carrier. (Panel A)
Size Dependency: The size of the pores determines the type
of nanoparticles that are preferably loaded into the silicon
particle. (Panel B) Dose Dependency: A larger number of
nanoparticles in the loading solution cause an increase in the
number of particles that are loaded into the pores. (Panel B)
Charge Dependency: Compatibly charged nanoparticles will
6
be attracted into the pores, whereas incompatible charges
will partially repel the nanoparticles and thus prevent them
to enter the pores.
FIG. 26, Panels A-B, present data for liposomes contain-
s ing SiRNA loaded into nanoporous silicon first stage par-
ticles. Panel A: Alexa 555 fluorescently labeled siRNAs
were encapsulated into nano-liposomes and loaded into the
1 st stage nano-vectors. The data show that the fluorescence
associated with the porous Silicon carrier increased with the
10 
amount of nanoliposomes. Y axis reads mean fluorescence in
Panel A. FIG. 26, Panel B, presents a graph showing relative
amount of liposomes released from first stage nanoporous
silicon particles. Y axis reads % of total amount of released
15 liposomes. To test the release of nano-liposome from 1st
stage carriers, the assembled multistage particles were incu-
bated with 10% fetal bovine serum (pH 7.4) and release of
nanoliposomes from 1 st stage particles was followed along
time using fluorimetry. Complete unloading was achieved in
20 about 36 h.
FIG. 27 demonstrates optimization of physical condition
for loading of quantum dots and PEG-FITC-SWNTs. Y axis
in Panel a and Panel b reads mean fluorescence. Porous
silicon particles were desiccated in a desiccator over night
25 and then mixed with the loading solution containing the
second stage nanoparticles. Loading efficiency in dry con-
dition was not significantly different than loading efficiency
in a wet environment (p value>0.5).
30 DEFINITIONS
Unless otherwise specified "a" or "an" means one or
more.
Biochemical environment of the target body site" refers
35 
to one or more intrinsic physiological conditions at the target
site, such as pH, salt conditions, temperature, or the presence
of target specific moieties, effective to initiate and promote
release of the particle content.
40 `Biodegradable" refers to a material that may dissolve or
degrade in a physiological medium or a biocompatible
polymeric material that may be degraded under physiologi-
cal conditions by physiological enzymes and/or chemical
conditions.
45 "Mucoadhesive" refers to the capability of the particle to
adhere to the mucosal layer, which lines the entire surface in
the small and large intestine. Adherence is mediated by
ligands grafted to the surface of the particles, which bind to
chemical receptors present in mucin or the surface of the
50 intestinal epithelial cells.
"Targeting moiety" is any factor that may facilitate tar-
geting of a specific site by a particle. For example, the
targeting moiety may be a chemical targeting moiety, a
physical targeting moiety, a geometrical targeting moiety or
55 a combination thereof. The chemical targeting moiety may
be a chemical group or molecule on a surface of the particle;
the physical targeting moiety may be a specific physical
property of the particle, such as a surface such or hydro-
phobicity; the geometrical targeting moiety includes a size
6o and a shape of the particle.
"Microparticle" means a particle having a maximum
characteristic size from 1 micron to 1000 microns, or from
1 micron to 100 microns. "Nanoparticle" means a particle
having a maximum characteristic size of less than 1 micron.
65 `Biocompatible" refers to a material that, when exposed
to living cells, will support an appropriate cellular activity of
the cells without causing an undesirable effect in the cells
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such as a change in a living cycle of the cells; a change in
a proliferation rate of the cells and a cytotoxic effect.
DETAILED DESCRIPTION
In embodiments of the invention, a composition that
includes two or more stages of particles, such that particles
of a later stage (smaller size particles) are contained in
particles of an earlier stage (larger particles), will potentially
provide one or more advantages for treating, preventing
and/imaging a physiological condition, such as a disease, in
a subject, which may be any animal with a blood system
(e.g., the subject may be a warm blooded animal, such as
mammal including human being). Embodiments of such
multistage composition provide one or more of the follow-
ing features or advantages: (1) an active agent, such as a
therapeutic agent or an imaging agent, is preferentially
delivered and/or localized to a particular target site in a body
of a subject. Preferential delivery and/or localization means
that an amount or concentration of the active agent delivered
to and/or localized at the target site is higher than an amount
or concentration of the active agent delivered to and/or
localized at other sites in the body of the subject; (2) a
multistage composition sequentially overcomes multiple
biological barriers in a body of the subject; and (3) a
multistage composition allows for simultaneous delivery
and localization at the same or different target site of
multiple active agents.
Biological Barriers
Following administration, an active agent, such as a
therapeutic or imaging agent, formulated conventionally or
in a nanovector, encounters a multiplicity of biological
barriers that adversely impact the agent's ability to reach an
intended target at a desired concentration. The biological
barrier may be, for example, an epithelial or endothelial
barrier, such as a blood-brain barrier or intestinal lumen
endothelium, that are based on tight junctions, that prevent
or limit para-cellular transport of an active agent. Each of the
endo/epithelial barrier includes a plurality of sequential
subbarriers, such as tight junction barriers, that owe their
molecular discrimination to one or more zonula occluden
proteins, and one or more additional biological membranes,
such as vascular endothelial basement membrane or a muso-
cal layer of the intestinal endothelium. Cells of the reticulo-
endothelial system may also act as a biological barrier
against an active agent encapsulated inside nanoparticles, as
such cells sequester/uptake the nanoparticles. The biological
barrier may be also represented by a cell membrane or a
nuclear membrane in a cell that an active agent has to come
through.
Multistage Delivery Vehicle
Since the biological barriers are sequential, overcoming
or bypassing such barriers has to be sequential too. Accord-
ingly, a delivery vehicle has been developed that, in embodi-
ments, acts in multiple stages. Each stage of the vehicle is
defined by a particle having a separate intended function,
which may be different from an intended function of a
particle of another stage. For example, a particle of one stage
is designed to target a specific body site, which may be
different from a site targeted by a particle of another stage,
and thus to overcome or bypass a specific biological barrier,
which is different from a biological barrier being overcome
or bypassed by a particle of another stage. A particle of each
subsequent stage is contained inside a particle of an imme-
diately preceding stage. A particle of any particular stage
may contain an active agent, such as a therapeutic agent or
an imaging agent, intended for use at this particular stage.
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In a preferred embodiment, a particle of the last stage is
an active agent formulated as a nanoparticle or alternatively
the last stage particle contains the active agent inside, while
a particle of any earlier stage per se may or may not
5 comprise an active agent. In some embodiments, in addition
to targeting a specific body site, a particle of each stage is
designed in such a way that it is capable to perform targeted
release of its content. In embodiments, the number and type
of stages in the multistage delivery vehicle depends on
io several parameters, including administration route and an
intended final target for the active agent. An embodiment of
a multistage delivery vehicle is illustrated on FIG. 1.
First Stage Particle
In some embodiments, the particle of the first stage is a
15 micro or nanoparticle. In some embodiments, the first stage
particle has a characteristic size of at least 500 microns or at
least 1 mm. Such a particle may be configured to contain
inside at least one micro or nanoparticle, which in turn may
contain inside at least one particle of a smaller size. The first
20 stage particle is any particle that is capable of containing
inside particles of a smaller size.
In some embodiments, the first stage particle is a top-
down fabricated particle, i.e., a particle prepared by top-
down microfabrication or nanofabrication methods, such as
25 photolithography, electron beam lithography, X-ray lithog-
raphy, deep UV lithography or nanoprint lithography. A
potential advantage of using the top-down fabrication meth-
ods is that such methods provide for a scaled up production
of particles that are uniform in dimensions.
30 The particle of the first stage may be configured to
overcome at least one of the following biological barriers: a
hemo-rheology barrier, a Reticulo-Endothelial System bar-
rier, an endothelial barrier, a blood brain barrier, a tumor-
associated osmotic interstitial pressure barrier, an ionic and
35 molecular pump barrier, a cell membrane barrier, an enzy-
matic degradation barrier, a nuclear membrane barrier or a
combination thereof.
The first stage particle may have a body that is defined by
a size and a shape of the particle and one or more reservoirs
40 inside the body. One or more second stage particles may be
contained inside the reservoir.
The body of the first stage particle comprises any appro-
priate material. Preferably, the material of the body of the
first stage particle is biocompatible. In some embodiments,
45 the body of the first stage particle comprises an oxide
material such as silicon oxide, aluminum oxide, titanium
oxide, or iron oxide; a semiconductor material, such as
silicon; a polymer or a polymer oxide material; or a ceramic
material. In some embodiments, the body of the first stage
50 particle comprises a biodegradable material, such as, for
example, nanoporous silicon. The biodegradable material
may be such that it degrades when exposed to a physiologi-
cal medium such as silicic acid.
In some embodiments, a material of the body of the first
55 stage particle is substantially the same in different regions of
the body. The shape of the first stage particle may depend on
the administration route. For example, the shape may be
configured to maximize the contact between the first stage
particle and a surface of the target site, such as endothelium
60 surface for intravascular administration or intestinal epithe-
lium for oral administration. Accordingly, for oral and
intravascular administration, the first stage particle may
have a selected non-spherical shape configured to maximize
the contact between the particle and endothelium surface.
65 Examples of appropriate shapes include, but are not limited
to, an oblate spheroid or a disc. For pulmonary administra-
tion, i.e., administration to lungs of the subject, the first stage
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particles may also have a selected non-spherical shape
configured to maximize a contact between the particle and
one of the epithelial tissues in lungs.
For pulmonary administration, i.e., an administration
route, which involves passing of the particle through lungs
of a subject, the first stage particle may also have a spicular
shape, which may facilitate entering of the particle from the
lungs into a body tissue, not necessarily through the blood
circulation.
Although top-down fabrication allows manufacturing par-
ticles having size in a wide range from 50 mu up to several
millimeters, for certain administration routes particular par-
ticle sizes may be preferred. For example, for intravascular
administration, a maximum characteristic size of the par-
ticle, e.g., a diameter for a disc-shaped particle, is preferably
sufficiently smaller than a radius of the smallest capillary. In
humans, such a radius is about 4 or 5 microns. Accordingly,
the maximum characteristic size of the particle are, in some
embodiments, less than about 3 microns, less than about 2
microns or less than about 1 micron.
In embodiments, the maximum characteristic size of the
first stage particle is from 500 mu to 3 microns, or from 700
mu to 2 microns. Yet in some embodiments for intravascular
administration in oncological applications, the maximum
characteristic size of the first stage particle is such that the
first stage particle could localize at the targeted vasculature
site without penetrating a fenestration in vascular cancer
endothelium. For such applications, the maximum charac-
teristic size of the first stage particle is greater than about
100 mu, or greater than about 150 mu, or greater than about
200 mu.
Yet in some embodiments for intravascular administra-
tion, the size of the first stage particle is such so that the
particle may penetrate the fenestration. Accordingly, the
maximum characteristic size in such applications is prefer-
ably less than about 200 mu, or less than about 150 mu, or
less than about 200 mu. In some embodiments, one may
select a size of the first stage particle that is selected to be
a critical radius of normal non-fenestrated vasculature for
targeting fenestrated vasculature as detailed in PCT patent
application No. PCT/US2006/038916 "Methods and Com-
positions for Targeting Fenestrated Vasculature" filed Sep.
27, 2006 to Paolo Decuzzi and Mauro Ferrari.
For oral administration, it may be preferable to use the
first stage particle that has a maximum characteristic size
greater than about 2 microns or greater than about 5 microns
or greater than about 10 microns. One advantage of using the
first stage particle of such size for oral administration is that
such particle may be too large to be endocytosed by intes-
tinal epithelial cells. The endocytosis by intestinal epithelial
cells has at least two potential disadvantages: 1) the content
of the first stage particle may be deactivated as it is pro-
cessed by the endothelial cell before it reaches the desired
target; 2) the potential toxicity of particular carrier, e.g. of
the material of the particle, is of greater concern if it is
endocytosed than if it is cleared through the gastrointestinal
tract.
In some embodiments, for oral administration, the first
stage particle has a size ranging from 500 microns to several
centimeters, or from 1 mm to 2 cm.
For pulmonary administration, the maximum character-
istic size of the first stage particle is preferably less than
about 20 microns but greater than about 5 microns, if a
targeted site is located in the lungs' air passages. For
targeting a site in alveoli, the maximum characteristic site
may be less than about 5 microns.
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In some embodiments, for subcutaneous administration, a
characteristic size of the first stage particle is from 50
microns to 1 mm; or from 100 microns to 1 mm.
One of the functions of the first stage particle, in embodi-
5 ments, is localization at a particular target site. For intra-
vascular administration, such target site may be a particular
vasculature site. For example, in anticancer applications, the
targeted vasculature site may be a tumor vasculature, such as
angiogenesis vasculature, coopted vasculature or renormal-
10 ized vasculature. The localization of the first stage particle at
the targeted site may be facilitated by geometrical factors,
such as the size and the shape of the particle.
For intravascular administration, the localization at the
15 targeted site may be also facilitated by one or more recog-
nition factors on the surface of the first stage particle. The
recognition factor may be a chemical targeting moiety, such
as a dendrimer, an antibody, an aptamer, which may be a
thioaptamer, a ligand or a biomolecule that binds a particular
20 receptor on the targeted site. For oral delivery, the chemical
moiety may comprise one or more mucoadhesive ligands, as
described in Table 1 of U.S. Pat. No. 6,355,270.
The selectivity of the targeting may be tuned by changing
chemical moieties of the surface of the particles. For
25 example, coopted vasculature is specifically targetted using
antibodies to angiopoietin 2; angiogenic vasculature is rec-
ognized using antibodies to vascular endothelial growth
factor (VEGF), basic fibroblast growth factor (FGFb) or
endothelial markers such as owP3 integrins, while renormal-
30 ized vasculature are recognized using carcinoembionic anti-
gen-related yell adhesion molecule 1 (CEACAMI),
endothelin-B receptor (ET-B), vascular endothelial growth
factor inhibitors gravin/AKAP12, a scallofldoing protein for
protein kinase A and protein kinase C, see, e.g., Robert S.
35 Korbel "Antiangiogenic Therapy: A Universal Chemosen-
sitization Strategy for Cancer?", Science 26 May 2006, vol
312, no. 5777, 1171-1175.
For targeting to non-circulating vasculature cells, the
binding between the first stage particle and the molecular
40 marker of the targeted vasculature site should be sufficiently
strong to overcome the drag force exerted by the flowing
blood. This objective may be satisfied by having a relatively
large planar surface area for specific binding and a relatively
low profile in a capillary's blood flow space, i.e., by having
45 the particle of the selected non-spherical shape, such as an
oblate spheroid or a disc.
The recognition factor may be also a physical recognition
moiety, such as a surface charge. The charge may be
introduced during the fabrication of the particle by using a
50 chemical treatment such as a specific wash. For example,
immersion of porous silica or oxidized silicon surface into
water may lead to an acquisition of a negative charge on the
surface, see, e.g., Behrens and Grier, J. Chem. Phys. 115
(14), (2001). P. 6716-6761. The surface charge may be also
55 provided by an additional layer or by chemical chains, such
as polymer chains, on the surface of the particle. For
example, polyethylene glycol chains may be a source of a
negative charge on the surface. Polyethylene glycol chains
may be coated or covalently coupled to the surface as
6o described in P. K. Jal, S. Patel, B. K. Mishra, Talanta 62
(2004) P1005-1028; S.W. Metzger and M. Natesan, J. Vac.
Sci. Technol. A 17(5), (1999) P 2623-2628; and M. Zhang,
T. A. Desai and M. Ferrari, Biomaterials, 19, (1998), p 953.
The positive charge is introduced, for example, by coating
65 the surface with a basic polymer, such as polylysine or by
covalently linking to the surface an amino containing mol-
ecule, such as 3-aminopropyltriethoxysilane.
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In some embodiments, modeling methods are applied for
selecting geometrical factors, such as a size and a shape,
and/or surface modification, such as chemical modification
and electrostatic modification, of the particle based on one
or more properties of the selected target site. Such modeling
methods are disclosed, for example, in 1) U.S. Provisional
Patent Application No. 60/829,075 "Particles for Cell Tar-
geting" filed Oct. 11, 2006 to Paolo Decuzzi and Mauro
Ferrari; 2) U.S. Provisional Patent Application No. 60/891,
584 "Endocytotic particle" filed Feb. 26, 2007 to Paolo
Decuzzi and Mauro Ferrari; 3) Decuzzi, P., Causa, F.,
Ferrari, M. & Netti, P. A. The effective dispersion of
nanovectors within the tumor microvasculature Ann Biomed
Eng 34, 633-41 (2006); 4) Decuzzi, P. & Ferrari, M. The
adhesive strength of non-spherical particles mediated by
specific interactions. Biomaterials 27, 5307-14 (2006); 5)
Decuzzi, P. & Ferrari, M. The role of specific and non-
specific interactions in receptor-mediated endocytosis of
nanoparticles. Biomaterials 28, 2915-22 (2007); 6) Decuzzi,
P., Lee, S., Bhushan, B. & Ferrari, M. Atheoretical model for
the margination of particles within blood vessels. Ann
Biomed Eng 33, 179-90 (2005); Decuzzi, P., Lee, S.,
Decuzzi, M. & Ferrari, M. Adhesion of microfabricated
particles on vascular endothelium: a parametric analysis.
Ann Biomed Eng 32, 793-802 (2004).
In some embodiments, the first stage particle is configured
to release the second stage particles from its reservoir at the
target site. The release of the second stage particles may be
performed according to a variety of mechanisms, including,
but not limited to, diffusion of the second stage particles
through the channels connecting the reservoir and the sur-
face of the first stage particle and degradation or erosion of
the body the first stage particle. For such a purpose, the first
stage particle is configured to have a characteristic release
time longer than a characteristic delivery time of the first
stage particle to its target site when administered to the
subject.
In some embodiments, the first stage particle is configured
to perform a release of the second stage particles from its
reservoir that is sustained over a period of time longer than
a characteristic delivery time of the first stage particle to its
target site when administered to the subject. In some
embodiments, the first stage particle is configured to release
the second stage particles over a time period longer than at
least 0.5 hr; or longer than at least 1 hr; or longer than at least
2 hr; or longer than at least 8 hr; or longer than at least 15
hr; or longer than 30 hr.
In some embodiments, physical localization and/or tar-
geted release of the first stage particle is initiated by one or
more intrinsic physiological conditions at the target site such
as pH, salt concentrations or temperature. In some embodi-
ments, physical localization and/or targeted release of the
first stage particle is initiated by exogenous stimulation.
Examples of exogenous stimulations include mechanical
activation, such activation by ultrasound; electromagnetic
activation, such an activation by visible, ultraviolet, near-
infrared or infrared light, radiofrequency or X-ray radiation;
magnetic radiation. For example, the first stage particle may
comprise a smart polymer, i.e., a polymer that contracts or
expand in a response to a specific stimulus, such as light,
temperature or pH. Smart polymers are described, for
example, in "In Situ Activation of Microencapsulated Drugs
(MSC-22866)," NASA Tech Briefs, Vol. 24, No. 9 (Septem-
ber 2000), page 64; "Externally Triggered Microcapsules
Release Drugs In Situ (MSC-22939), NASA Tech Briefs,
(April 2OO2), page 50; and U.S. Pat. No. 6,099,864 issued to
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Morrison and Mosier on Aug. 8, 2000. In some cases, more
than one exogenous stimulation is used together for acti-
vating release.
To increase the localization/targeting efficiency, the first
5 stage particle may utilize multiple, i.e., more than one
recognition/localization/targeting factors, which preferably
do not interfere with each other. For example, the first
particle may have the selected non-spherical shape as dis-
cussed above and at the same time carry tumor-targeting
10 
antibodies on its surface.
In some embodiments, the surface of the first stage
particle may be coated with polymer chains partially or
completely. The polymer chains may be added after the
15 fabrication of the intravascular stage particle. The polymer
chains may be hydrophilic chains, such as polyethylene
glycol (PEG) chains or synthetic glycocalix chains, which
may be used for overcoming the uptake of the particle by
cell of the reticulo-endothelial system and, thus, extending
20 the blood circulation of the intravascular stage particle. The
hydrophilic groups may also serve for enhancement of
solubility of the multistage delivery devices.
A variety of materials may be derivatized with polymer
chains. For example, when the particle's surface material
25 comprises a polymer, polymer chains may be attached by
linking carboxylic groups of the polymer and amine or
hydroxyl groups in the polymer chains; if the particle's
surface material comprises metal such as gold, the polymer
chains may be attached to the surface via thiol chemistry;
30 
when the particle's surface material comprises an oxide,
such silicon oxide, titanium oxide or aluminum oxide, the
polymer chains may be attached using silane chemistry.
In addition to one or more second stage particles, the
35 reservoir of the first stage particle may contain one or more
additional agents. Such additional agent may include an
additional active agent, such as a therapeutic agent or an
imaging agent, a targeting agent, one or more penetration
enhancers or any combination thereof. The penetration
40 enhancer may include one or more compounds listed in
Table 1.
TABLE 1
Penetration Enhancers
45
Class of Enhancer Specific Examples
Bile Salts Glyo-deoxycholate
Tamro-dexoycholate
Tauro-chenodeoxycholate
50 Glyco-chenodexycholate
Taurocholate
Glycocholate
Glycoursocholate
Tauroursocholate
Dexoycholate
55 Chenodeoxycholate
Cholate
Ursocholate
Non-ionic Surfactants Polyoxyethylene (POE) ethers (e.g., Brij,
Texaphor)
Alkylphenoxy-POEs (Triton, Igepal,
60
Surfonic)
Anionic Surfactants sodium dodecyl sulfate
dioctyl sodium sulfosuccinate
Lecithins Lysolecithin
Medium chain glycerides mono-, di-, or triglycerides of C8, CIO, or
C12 fatty acids
Medium chain fatty acids sodium caprylate
65 sodium caprate
sodium laurate
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TABLE 1-continued
Penetration Enhancers
Class of Enhancer Specific Examples
Salicylates sodium salicylate
Acylcarnitines decylcarnitine
laurylcarnitine
myristoylcarnitine
Acylcholines Laurylcholine
Palmitoylcholine
Acyl amino acids N-laurylphenylglycine
N-palmitoylglycine
Calcium chelators Ethylenediaminetetraacetic acid (EDTA)
Peptides PZ-peptide
Zonula occludens toxin (ZOT)
For intravascular administration, the penetration enhanc-
ers may include a basement membrane penetration enhancer
that may act against the basement membrane, and/or one or
more penetration enhancers, that may act against tight
junction proteins (TJPs). An example of the basement mem-
brane penetration enhancer is metalloproteinase, such as
Collagenase IV, MMP-2, and MMP-9. An example of the
anti-TJP penetration enhancer is zonula occluden toxin.
Anti-TJP penetration enhancers and strategies for modulat-
ing tight junction permeability are detailed, for example, in
Gonzalez-Mariscal, L., Nava, P. and Hernandez, S. J.
Membr. Biol., 2005. 207(2): p. 55-68.
FIGS. 2A-B illustrate the action of penetration enhancer
upon localization of the first stage particle at the targeted
vasculature site, in accordance with an embodiment. The
first stage particle releases the permeation enhancers that
generate in the targeted vasculature one or more fenestra-
tions, through which the second stage particles penetrate
into the vasculature.
In some embodiments, the first stage particle has one or
more channels fluidically connecting the reservoir with the
surface, that may be in contact with endo or epithelial cells.
For intravascular administration, such first stage particle
may be a micro or nano fabricated particle, such as those
detailed in U.S. Patent Application Publication No 2003/
0114366 and U.S. Pat. No. 6,107,102, and for oral admin-
istration, such first stage particle may be a micro or fabri-
cated particle, such as the ones disclosed in U.S. Pat. No.
6,355,270.
In some embodiments, the reservoir and the channels are
pores in the body of first stage particle. In such case, the first
stage particle may comprise a porous or nanoporous mate-
rial. Preferably, the pores of the porous or nanoporous
material may be controlled to achieve a desired load of the
next stage particles and a desired release rate. The nanop-
orous material with controllable pore size may be an oxide
material, such as silicon oxide, aluminum oxide, titanium
oxide, or iron oxide. Fabrication of nanoporous oxide par-
ticles, also known as sol gel particles, is detailed, for
example, in Paik J. A. et. al. J. Mater. Res., Vol. 17, August
2002. The nanoporous material with controllable pore size
may be also nanoporous silicon. For details of fabrication of
nanoporous silicon particles, see Cohen M. H. et. al. Bio-
medical Microdevices 5:3, 253-259, 2003. Control of pore
density, size, shape and/or orientation may be accomplished
by changing electrical current and etching time during
formation of nanoporous silicon from non-porous silicon.
Control of pore density, size, shape and/or orientation may
be also accomplished by varying doping in non-porous
silicon used for formation of nanoporous silicon. Thus, pore
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size, density, size, shape and /or orientation of nanoporous
may be configured for efficient loading of the second stage
particles.
In some embodiments, pore size in nanoporous first stage
5 particles may be, for example, from about 1 rim to about 200
rim; or from about 2 nm to about 100 rim. In some cases,
pore size in nanoporous first stage particle may be from
about 3 to about 10 rim or from about 5 to about 7 rim. Yet
in some cases, pore size in nanoporous first stage particle
to may be from about 10 to about 60 mu, or from about 20 to
about 40 rim.
In some embodiments, to facilitate loading of the second
stage particles into pores of the porous or nanoporous
material may be modified chemically and/or electrostatically
15 to make it compatible with chemical and/or electrostatical
surface properties of the second stage particles. For
example, for loading negatively charged second stage par-
ticles, it may be preferable to use positively charged pore
surface. The positive charge may be achieved, for example,
20 by depositing on pore surface an amino-containing mol-
ecule, such as 3-aminopropyltriethoxysilane. For loading
positively charged second stage particles, it may be prefer-
able to use negatively charged pore surface. The negative
pore surface charge may be accomplished, for example, by
25 oxidizing pore surface with water.
In some embodiments, the first stage particle has no
channels at all. Such particle may comprise, for example, a
biodegradable material. For oral administration, the material
may be designed to erode in the GI tract. As examples, the
30 first stage particle may be formed of metals, such as iron,
titanium, gold, silver, platinum, copper, and alloys and
oxides thereof. The biodegradable material may be also a
biodegradable polymer, such as polyorthoesters, polyanhy-
drides, polyamides, polyalkylcyanoacrylates, polyphospha-
35 zenes, and polyesters. Exemplary biodegradable polymers
are described, for example, in U.S. Pat. Nos. 4,933,185,
4,888,176, and 5,010,167. Specific examples of such bio-
degradable polymer materials include poly(lactic acid),
polyglycolic acid, polycaprolactone, polyhydroxybutyrate,
40 poly(N-palmitoyl-trans-4-hydroxy-L-proline ester) and poly
(DTH carbonate).
In some embodiments, the body of the first stage particle
includes two or more regions configured to contain different
populations of second stage particles. For example, the body
45 of the first stage particle may have a first region configured
to contain a first population of second stage particles and a
second region configured to contain a second population of
second stage particles. For instance, the first stage particle
formed of porous nanoporous material may be such that its
5o body has two or more porous regions that differ from each
other. The body of the nanoporous first stage particle may
include a first porous region and second porous region that
differ from each other in at least one property such as a pore
density, pore geometry; pore charge, pore surface chemistry,
55 pore orientation or any combination thereof. Such first and
second regions may be configured respectively to contain a
first and a second population of second stage particles.
In some embodiments, the first and second populations of
second stage particles differ in at least one property such as
60 size; shape; surface chemical modification; surface charge or
a combination thereof.
In some embodiments, the first and second populations of
second stage particles contain the same active agent. Yet, in
some embodiments, the first and second population of
65 second stage particles contain respectively a first active
agent and a second active agent that are different from each
other.
US 10,143,658 B2
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The first and second populations of second stage particles
may be configured to perform different functions. For
example, in some embodiments, the first and second popu-
lations may be configured to target respectively a first and
second target sites that are different from each other.
In some embodiments, the first population are configured
to target a particular site in a body of the subject, while the
second population is configured to free circulate in the blood
system of the subject.
In some embodiments, the first and the second population
target the same target site in a body of the subject but
perform a different function at the body site. For example,
the first population contains a therapeutic agent to be deliv-
ered to the target site, while the second population contains
an imaging agent to be delivered to the target site for
imaging or visualizing the target site.
The first and the second regions of the body of the first
stage particle may be such that at least one of them is a
biodegradable region. Preferably, both the first and the
second regions of the body of the first stage particle is
biodegradable.
The first and the second regions of the body of the first
stage particle may have different characteristic time for
releasing the first and the second population of second stage
particles. In some embodiments, both characteristic time for
releasing the first population of second stage particles from
the first region and characteristic time for releasing the
second population of second stage particles from the second
region may be greater that a characteristic for delivery
and/or localization of the first stage particle at its target site
when administered to the subject.
In some embodiments, the first stage particle is configured
to separate into a first component that includes the first
region and a second component that includes the second
region when being exposed to a physiological medium, such
as a medium that may be present at a target site of the first
stage particle. Such exposure may occur, for example, when
the particle is administered to the subject.
In some embodiments, the first and the second regions of
the body of the first stage particle are configured to perform
a different function when the particle is administered to the
subject. For example, the first and the second region of the
body of the first stage particle may be configured to over-
come respectively the first and the second biological barriers
that are different from each other. Such biological barriers
may be each selected, for example, from a hemo-rheology
barrier, a Reticulo-Endothelial System barrier, an endothe-
lial barrier, a blood brain barrier, a tumor-associated osmotic
interstitial pressure barrier, an ionic and molecular pump
barrier, a cell membrane barrier, an enzymatic degradation
barrier, a nuclear membrane barrier or a combination
thereof.
Second Stage Particle
The second stage particle may be any micro or nanopar-
ticle that may fit inside the reservoir of the first stage
particle. For example, in certain embodiments, for oral or
pulmonary administration, the second stage particle is the
same as the first stage particle for intravascular administra-
tion.
The particle of the second stage may be configured to
overcome at least one barrier selected from a hemo-rheology
barrier, a Reticulo-Endothelial System barrier, an endothe-
lial barrier, a blood brain barrier, a tumor-associated osmotic
interstitial pressure barrier, an ionic and molecular pump
barrier, a cell membrane barrier, an enzymatic degradation
barrier, a nuclear membrane barrier or a combination
thereof.
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The composition, size and shape of the second stage
particle are not particularly limited. For example, for many
administration routes, the second stage particle may be a
lipid based particle, such as a liposome, a micelle or lipid
5 encapsulated perfluorocarbon emulsion; an ethosome; a car-
bon nanotube, such as single wall carbon nanotube; a
fullerene nanoparticle; a metal nanoparticle, such gold
nanoshell or triangular silver nanoparticle; a semiconductor
nanoparticle, such as quantum dot or boron doped silicon
10 
nanowire; a polymer nanoparticle, such as particles made of
biodegradable polymers and ion doped polyacrylamide par-
ticles; an oxide nanoparticle, such as iron oxide particle, a
polymer coated iron oxide nanoparticle or a silicon oxide
15 
particle; a viral particle, such as an engineered viral particle
or an engineered virus-polymer particle; a polyionic particle,
such as leashed polycations; a ceramic particle, such as silica
based ceramic nanoparticles, or a combination thereof.
In some embodiments, the second stage particle is con-
20 figured to target a particular target site in a body of the
subject. Such target site may be the same or different from
the target site targeted by the first stage particle.
For example, the surface of the second stage particle may
have one or more antibodies that may conjugate with surface
25 
marker antigens of certain types of cells. Thus, the second
stage particle may selectively target cells that carry such
marker antigens. The examples of cells that carry surface
marker antigens include stem or clonogenic cells and tumor
cells. The surface marker antigens on stem or clonogenic
30 cells may be targeted by CD33 antibody. A number of
monoclonal antibodies to tumor specific antigens are avail-
able, see, e.g., pp. 301-323 of CANCER, 3rd Ed., De Vita,
et. al. eds; 7aneway et. al. Immunology 5th Edition, Garland
Press, New York, 2001; A. N. Nagappa, D. Mukherjee & K.
35 Anusha "Therapeutic Monoclonal Antibodies", PharmaBiz.
com, Wednesday, Sep. 22, 2004. Table 2 presents FDA
approved monoclonal antibodies for treatment of cancer.
11OHNIM
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MAb Name
Trade
Name Used to Treat: Approved in
Rituximab Rituxan Non-Hodgkin lymphoma 1997
Trastuzumab Herceptin Breast cancer 1998
Gemtuzumab Mylotarg Acute myelogenous 2000
45 ozogamicin* leukemia (AML)
Alemtuzumab Campath Chronic lymphocytic 2001
leukemia (CLL)
Ibritumomab tiuxetan* Zevalin Non-Hodgkin lymphoma 2002
Tositumomab* Bexxar Non-Hodgkin lymphoma 2003
Cetuximab Erbitux Colorectal cancer 2004
50 Head & neck cancers 2006
Bevacizumab Avastin Colorectal cancer 2004
In some embodiments, the second stage particle is con-
figured to freely circulate in a blood system of the subject
55 upon being released from the first stage particle. In some
cases, such second stage particle may have a surface free of
targeting moieties, such as antibodies. The free circulating
second stage particle may be used, for example, as to report
of therapeutic action a therapeutic agent associated with a
60 first stage particle per se.
In some embodiments, the surface of the second stage
particle does not have hydrophilic polymer chains, such as
polyethylene glycol (PEG) disposed on it. In certain cases,
this may be an advantage of the multistage delivery vehicle
65 as PEG chains are usually attached to liposomes and other
nanoparticles to delay recognition and sequestration by
macrophages of the reticulo-endothelial system. Unfortu-
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nately, the PEG chains may also hide antibodies on the
nanoparticles surfaces and thus inhibit the targeting/local-
ization ability of the antibodies. In the multistage delivery
vehicle, PEGS attached to the first stage particle may per-
form shielding from the RES macrophages. Although the 5
PEGS may hide antibodies on the first stage particle, the
recognition/localization capability of the first stage particle
is not limited to the antibodies, as other factors such as the
particle's size and shape also may contribute to such capa-
bility. In some embodiments, the surface of the second stage io
particle has hydrophilic polymer chains, such as PEG
chains, disposed on it.
In some embodiments, the surface of second stage particle
is modified, for example, to facilitate the second stage
particle's ability to load into a reservoir of the first stage 15
particle and/or to facilitate the second stage particle's ability
to reach its target site. The surface modification may include
a chemical modification of the surface of the second stage
particle and/or electrostatic modification of the surface of
the second stage particle. For example, to facilitate loading 20
of the second stage particles into a porous or nanoporous
first stage particle, the surface of the second stage particles
may be modified so that its properties are compatible with
surface properties of pores of the porous or nanoporous first
stage particle. For example, when the pores of the porous or 25
nanoporous first stage particle are positively charged it may
be preferably to modify the surface of the second stage
particles so that they are electrostatically neutral or have a
negative surface charge; while when the pores of the porous
or nanoporous first stage particle are negatively charged, it 30
may be preferably to modify the surface of the second stage
particles so that they are electrostatically neutral or have a
positive surface charge. The chemical and/or electrostatic
surface modification of the second stage particles may be
performed using the same methods as detailed above to the 35
first stage particles.
For lipid containing second stage particles, such as lipo-
somes or micelles, the electrostatic modification may be
performed by incorporating in their lipid layers lipids that
may affect the electrostatic charge of the liposome. For 40
example, to form a positively charged cationic lipid con-
taining particle, one may use cationic lipids, such as 1,2-
Dioleyl-3-trymethylammoniumpropane (DOTAP); to form a
negatively charged anionic lipid containing particle, anionic
lipids, such as dioleoylphosphatidyl glycerol (DOPG); and 45
to form a neutral lipid containing particle one may use,
neutral lipids, such as DOPC.
In some embodiments, upon binding to the targeted cell or
cells, the second stage particle may release its content into
the cell's cytoplasm. In some embodiments, such release is 50
activated by exogenous factors, such as electromagnetic
radiation. For fullerene nanoparticles and carbon nanotubes,
such radiation may be radio-frequency radiation, while for
gold-shell nanoparticles, the radiation may be a near-infra-
red radiation. Activation of nanoparticulates by exogenous 55
radiation is detailed, for example, Hirsch, L. R., Halas, N. J.
& West, J. L. Anal. Chem. 75, 2377-2381 (2003); Hirsch, L.
R., Halas, N. J. & West, J. L. Proc. Natl Acad. Sci. USA 100,
13549-13554 (2003); and O'Neal, D. P., Halas, N. J. & West,
J. L. Cancer Lett. 209, 171-176 (2004). 60
In some embodiments, the content of the second stage
particle is one or more active agents per se. In some
embodiments, the second stage particle contains inside a
third stage particle, which itself contains inside one or more
active agents. The third stage particle may be, for example, 65
a particle, that is small enough to be able to cross a nuclear
membrane of the targeted cell. Thus, the third stage particle
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may serve for delivering to the cell's nucleus an active
agent, that may be an agent acting against nucleic acids or
a gene therapeutic agent. To be able to cross the nuclear
membrane, the third stage particle may range from about 3
mu to about 10 mu. The ability to deliver nanoparticles in 3
mu to 10 mu size range may be one of the advantages of the
multistage delivery vehicle as a conventional administration
of such particles via injection usually results in their imme-
diate globular clearance.
In some embodiments, the multistage vehicle includes a
third stage. The third stage may be any nanoparticle that may
fit inside the second stage particle. As with the second stage
particle, the third stage particle may be a lipid based particle,
such as a liposome, a micelle or lipid encapsulated perfluo-
rocarbon emulsion; an ethosome; a carbon nanotube, such as
single wall carbon nanotube; a fullerene nanoparticle; a
metal nanoparticle, such gold nanoshell or triangular silver
nanoparticle; a semiconductor nanoparticle, such as quan-
tum dot or boron doped silicon nanowire; a polymer nano-
particle, such as particles made of biodegradable polymers
and ion doped polyacrylamide particles; an oxide nanopar-
ticle, such as iron oxide particle, a polymer coated iron oxide
nanoparticle or a silicon oxide particle; a viral particle, such
as an engineered viral particle or an engineered virus-
polymer particle; a polyionic particle, such as leashed poly-
cations; a ceramic particle, such as silica based ceramic
nanoparticles, or a combination thereof. In some embodi-
ments, the third stage particle is a nucleic acid nanoparticle,
such as a small interfering RNA (siRNA) particle.
Loading Later Stage Particles into a Reservoir of Earlier
Stage Particle
Later stage particles may be introduced into a earlier stage
particle of an earlier stage by any appropriate technique. In
some embodiments, one may soak nanoporous earlier stage
particles fabricated in a solution containing a carrying fluid
and the later stage particles, which may enter pores of the
earlier stage particle via capillary action and/or diffusion.
The carrying fluid may be a liquid that is biologically
non-harmful and that is neutral with respect to the earlier
stage particle's material. An example of the carrying fluid
may be phosphate buffer saline (PBS) or a deionized water.
The solution may also contain one or more additional agents,
such one or more additional therapeutic agents and one or
more appropriate penetration enhancers, desired to be intro-
duced in the first stage particle. To maximize a load of the
later stage particles, one may use a solution that has a
saturated concentration of the later stage particles.
The earlier stage particles may be introduced into the
solution in a form of suspension. Preparation of nanoporous
particles suspension is detailed, for example, in U.S. patent
application Ser. No. 2003/0114366. Pores of the nanoporous
particles may be dried prior their submerging in the solution
containing the later stage particles.
In some embodiments, the solution containing the later
stage particles pores may be degassed prior to the introduc-
tion of the earlier stage particles. Then, the earlier stage
particles may be submerged in the degassed solution in a
sealed chamber. The earlier stage particles may be subjected
to reduced pressure to ensure that trapped air is forced from
the pores in the particles. Then the earlier stage particles may
be fully immersed in the solution and the pressure in the
sealed chamber may be elevated slightly above atmospheric
to make sure that the solution enters the pores of the earlier
stage particles. The earlier stage particles may then be
trapped on a filter and dried using one of the three methods
described below.
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In some embodiments, to remove any trapped air within
the reservoirs in the submerged earlier stage particles, the
pressure within the chamber is reduced and then raised
slightly above atmospheric pressure.
In some embodiments, after filling the solution into the 5
pores of the earlier stage particles, drying is achieved by one
or more of the following three methods. Water may be
removed by evaporation under reduced pressure in a vacuum
chamber, or by passage of a stream of warm air or an inert
gas such as nitrogen over the surface particles collected on io
a filter, or by freeze drying. In the case of freeze drying, a
flat heat exchanger may be placed in good thermal contact,
e.g. directly below, the filter, on which the earlier stage
particles have been collected. Refrigerant fluid at tempera-
tures ranging from —20° C. to —60° C., such as Freon, or a 15
cold liquid, such as liquid nitrogen, may be passed through
the heat exchanger flowing into port and passing out port in
order to freeze any water remaining within the pores. The
pressure may be then reduced until all the water sublimes.
In some embodiments, for loading later stage particles 20
into nanoporous earlier stage particles, a solution containing
the earlier stage nanoporous particles, the later stage par-
ticles and a carrier liquid is prepared. The carrier liquid may
be a physiological buffer, such as Tris-HCI. A concentration
of the carrier liquid may be selected by using standard 25
techniques to maximize loading of the later stage particle
into the nanoporous earlier stage particles. For example, in
some embodiments, for Tris-HCI, the optimal concentration
may be selected from 1 to 500 mM.
Geometrical properties of the later stage particles, such as 30
size and shape, may be selected to be compatible pore
properties of the nanoporous earlier stage particles, such as
pore density, pore size, and pore orientation.
In some embodiments, loading of the later stage particle
into the nanoporous earlier stage particles is facilitated by 35
agitating the solution containing both the later stage and
earlier stage particles. Such agitation may be performed by
spinning the solution in a rotating wheel. Agitation condi-
tions, such as a rotation speed of the rotating wheel, may be
optimized using standard techniques to achieve a desired 40
loading degree and/or loading time.
In some embodiments, loading of the later stage particles
into the earlier stage nanoporous particles is controlled by
varying a concentration of the later stage particles in the
solution. In some embodiments, the higher load may be 45
achieved by using a higher concentration of the later stage
particles in the solution. Yet, in some embodiments, one may
achieve a higher load of the later stage particles by using a
concentration of the later stage particles, which is lower than
the highest possible concentration of the later stage particles 50
in the solution. Determining a concentration maximizing
loading of the later stage particles in the nanoporous earlier
stage particles may be performed using standard methods.
In some embodiments, loading of the later stage particles
into the earlier stage nanoporous particles is controlled by 55
modifying a pore surface of the nanoporous earlier stage
particles and/or a surface of the later stage particles in order
to make them more compatible. Such modifying may be
performed by modifying surface chemical groups on either
surface and/or by modifying an electrical charge on either 60
surface. For example, in some embodiments, to achieve a
higher load of the later stage particle, one may use nega-
tively charged surface of the later stage particles and posi-
tively charged porous surface of the earlier stage nanoporous
particles or positively charged surface of the later stage 65
particles and negatively charged porous surface of the earlier
stage nanoporous particles. In some embodiments, a pore
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surface of the nanoporous earlier stage particles and a
surface of the later stage particles are modified with chemi-
cal groups compatible with each other. For example, one of
the pore surface of the nanoporous earlier stage particles and
the surface of the later stage particles may be modified with
carboxy groups; while the other may be modified with
amino groups.
Active Agent
The active agent may be a therapeutic agent, an imaging
agent or a combination thereof. The active agent may be any
appropriate agent that may be released from a particle
containing it. The selection of the active agent depends on
the application.
When the active agent is not a particle of any stage per se,
it may be introduced into particle using any appropriate
technique. For example, when the active agent is doxorubi-
cin, it may be introduced in a liposome particle using a
protocol detailed in Working Example 4.
When the active agent is a particle of one of the stages of
multistage delivery vehicle, the active agent may introduced
using one of the methods disclosed above.
Therapeutic Agent
The therapeutic agent may be any physiologically or
pharmacologically active substance that may produce a
desired biological effect in a targeted site in an animal, such
as a mammal or a human. The therapeutic agent may be any
inorganic or organic compound, without limitation, includ-
ing peptides, proteins, nucleic acids, and small molecules,
any of which may be characterized or uncharacterized. The
therapeutic agent may be in various forms, such as an
unchanged molecules, molecular complex, pharmacologi-
cally acceptable salt, such as hydrochloride, hydrobromide,
sulfate, laurate, palmitate, phosphate, nitrite, nitrate, borate,
acetate, maleate, tartrate, oleate, salicylate, and the like. For
acidic therapeutic agent, salts of metals, amines or organic
cations, for example, quaternary ammonium, may be used.
Derivatives of drugs, such as bases, esters and amides also
may be used as a therapeutic agent. A therapeutic agent that
is water insoluble may be used in a form that is a water
soluble derivative thereof, or as a base derivative thereof,
which in either instance, or by its delivery, is converted by
enzymes, hydrolyzed by the body pH, or by other metabolic
processes to the original therapeutically active form.
The therapeutic agent may be a chemotherapeutic agent,
an immunosuppressive agent, a cytokine, a cytotoxic agent,
a nucleolytic compound, a radioactive isotope, a receptor,
and a pro-drug activating enzyme, which may be naturally
occurring or produced by synthetic or recombinant methods,
or any combination thereof.
Drugs that are affected by classical multidrug resistance,
such as vinca alkaloids (e.g., vinblastine and vincristine), the
anthracyclines (e.g., doxorubicin and daunorubicin), RNA
transcription inhibitors (e.g., actinomycin-D) and microtu-
bule stabilizing drugs (e.g., paclitaxel) may have particular
utility as the therapeutic agent.
A cancer chemotherapy agents may be a preferred thera-
peutic agent. Useful cancer chemotherapy drugs include
nitrogen mustards, nitrosorueas, ethyleneimine, alkane sul-
fonates, tetrazine, platinum compounds, pyrimidine analogs,
purine analogs, antimetabolites, folate analogs, anthracy-
clines, taxanes, vinca alkaloids, topoisomerase inhibitors
and hormonal agents. Exemplary chemotherapy drugs are
Actinomycin-D, Alkeran, Ara-C, Anastrozole, Asparagi-
nase, BiCNU, Bicalutamide, Bleomycin, Busulfan, Capecit-
abine, Carboplatin, Carboplatinum, Carmustine, CCNU,
Chlorambucil, Cisplatin, Cladribine, CPT-11, Cyclophosph-
amide, Cytarabine, Cytosine arabinoside, Cytoxan, Dacar-
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bazine, Dactinomycin, Daunorubicin, Dexrazoxane, Doc-
etaxel, Doxorubicin, DTIC, Epirubicin, Ethyleneimine,
Etoposide, Floxuridine, Fludarabine, Fluorouracil, Fluta-
mide, Fotemustine, Gemcitabine, Herceptin, Hexamethyl-
amine, Hydroxyurea, Idarubicin, Ifosfamide, Irinotecan,
Lomustine, Mechlorethamine, Melphalan, Mercaptopurine,
Methotrexate, Mitomycin, Mitotane, Mitoxantrone, Oxali-
platin, Paclitaxel, Pamidronate, Pentostatin, Plicamycin,
Procarbazine, Rituximab, Steroids, Streptozocin, STI-571,
Streptozocin, Tamoxifen, Temozolomide, Teniposide, Tetra-
zinc, Thioguanine, Thiotepa, Tomudex, Topotecan, Treosul-
phan, Trimetrexate, Vinblastine, Vincristine, Vindesine,
Vinorelbine, VP-16, and Xeloda.
Useful cancer chemotherapy drugs also include alkylating
agents, such as Thiotepa and cyclosphosphamide; alkyl
sulfonates such as Busulfan, Improsulfan and Piposulfan;
aziridines such as Benzodopa, Carboquone, Meturedopa,
and Uredopa; ethylenimines and methylamelamines includ-
ing altretamine, triethylenemelamine, trietylenephosphor-
amide, triethylenethiophosphaoramide and trimethylolom-
elamine; nitrogen mustards such as Chlorambucil,
Chlomaphazine, Cholophosphamide, Estramustine, Ifosf-
amide, mechlorethamine, mechlorethamine oxide hydro-
chloride, Melphalan, Novembiehin, Phenesterine, Predni-
mustine, Trofosfamide, uracil mustard; nitroureas such as
Cannustine, Chlorozotocin, Fotemustine, Lomustine,
Nimustine, and Ranimustine; antibiotics such as Aclacino-
mysins, Actinomycin, Authramycin, Azaserine, Bleomycins,
Cactinomycin, Calicheamicin, Carabicin, Carminomycin,
Carzinophilin, Chromoinycins, Dactinomycin, Daunorubi-
cin, Detorubicin, 6-diazo-5-oxo-L-norleucine, Doxorubicin,
Epirubicin, Esorubicin, Idambicin, Marcellomycin, Mito-
mycins, mycophenolic acid, Nogalamycin, Olivomycins,
Peplomycin, Potfiromycin, Puromycin, Quelamycin, Rodo-
rubicin, Streptonigrin, Streptozocin, Tubercidin, Ubenimex,
Zinostatin, and Zorubicin; anti-metabolites such as Metho-
trexate and 5-fluorouracil (5-FU); folic acid analogues such
as Denopterin, Methotrexate, Pteropterin, and Trimetrexate;
purine analogs such as Fludarabine, 6-mercaptopurine,
Thiamiprine, and Thioguanine; pyrimidine analogs such as
Ancitabine, Azacitidine, 6-azauridine, Cannofur, Cytara-
bine, Dideoxyuridine, Doxifluridine, Enocitabine, Floxuri-
dine, and 5-FU; androgens such as Calusterone, Dromo-
stanolone Propionate, Epitiostanol, Rnepitiostane, and
Testolactone; anti-adrenals such as aminoglutethimide,
Mitotane, and Trilostane; folic acid replenisher such as
frolinic acid; aceglatone; aldophosphamide glycoside; ami-
nolevulinic acid; Amsacrine; Bestrabucil; Bisantrene; Eda-
traxate; Defofamine; Demecolcine; Diaziquone; Elfornith-
ine; elliptinium acetate; Etoglucid; gallium nitrate;
hydroxyurea; Lentinan; Lonidamine; Mitoguazone; Mitox-
antrone; Mopidamol; Nitracrine; Pentostatin; Phenamet;
Pirarubicin; podophyllinic acid; 2-ethylhydrazide; Procar-
bazine; PSKO; Razoxane; Sizofrran; Spirogermanium;
tenuazonic acid; triaziquone; 2,2',2"-trichlorotriethylamine;
Urethan; Vindesine; Dacarbazine; Mannomustine; Mito-
bronitol; Mitolactol; Pipobroman; Gacytosine; Arabinoside
("Ara-C"); cyclophosphamide; thiotEPa; taxoids, e.g., Pacli-
taxel (TAXOL(k, Bristol-Myers Squibb Oncology, Princ-
eton, N.7.) and Doxetaxel (TAXOTEREO, Rhone-Poulenc
Rorer, Antony, France); Chlorambucil; Gemcitabine; 6-thio-
guanine; Mercaptopurine; Methotrexate; platinum analogs
such as Cisplatin and Carboplatin; Vinblastine; platinum;
etoposide (VP-16); Ifosfamide; Mitomycin C; Mitoxan-
trone; Vincristine; Vinorelbine; Navelbine; Novantrone;
Teniposide; Daunomycin; Aminopterin; Xeloda; Ibandro-
nate; CPT-11; topoisomerase inhibitor RFS 2000; difluo-
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romethylornithine (DMFO); retinoic acid; Esperamicins;
Capecitabine; and pharmaceutically acceptable salts, acids
or derivatives of any of the above. Also included are
anti-hormonal agents that act to regulate or inhibit hormone
5 action on tumors such as anti-estrogens including for
example Tamoxifen, Raloxifene, aromatase inhibiting 4(5)-
imidazoles, 4 Hydroxytamoxifen, Trioxifene, Keoxifene,
Onapristone, And Toremifene (Fareston); and anti-andro-
gens such as Flutamide, Nilutamide, Bicalutamide, Leupro-
io lide, and Goserelin; and pharmaceutically acceptable salts,
acids or derivatives of any of the above.
Cytokines may be also used as the therapeutic agent.
Examples of such cytokines are lymphokines, monokines,
and traditional polypeptide hormones. Included among the
15 cytokines are growth hormones such as human growth
hormone, N-methionyl human growth hormone, and bovine
growth hormone; parathyroid hormone; thyroxine; insulin;
proinsulin; relaxin; prorelaxin; glycoprotein hormones such
as follicle stimulating hormone (FSH), thyroid stimulating
20 hormone (TSH), and luteinizing hormone (LH); hepatic
growth factor; fibroblast growth factor; prolactin; placental
lactogen; tumor necrosis factor-a and -(3; mullerian-inhib-
iting substance; mouse gonadotropin-associated peptide;
inhibin; activin; vascular endothelial growth factor; integrin;
25 thrombopoietin (TPO); nerve growth factors such as NGF-(3;
platelet growth factor; transforming growth factors (TGFs)
such as TGF-a and TGF-(3; insulin-like growth factor-I and
-II; erythropoietin (EPO); osteoinductive factors; interferons
such as interferon-a, -(3 and -y; colony stimulating factors
30 (CSFs) such as macrophage-CSF (M-CSF); granulocyte-
macrophage-CSF (GM-CSF); and granulocyte-CSF
(GCSF); interleukins (ILs) such as IL-1, IL-la, IL-2, IL-3,
IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, IL-11, IL-12, IL-15; a
tumor necrosis factor such as TNF-a or TNF-(3; and other
35 polypeptide factors including LIE and kit ligand (KL). As
used herein, the tern cytokine includes proteins from natural
sources or from recombinant cell culture and biologically
active equivalents of the native sequence cytokines.
Imaging Agent
40 The imaging agent may be any substance that provides
imaging information about a targeted site in a body of an
animal, such as a mammal or a human being. The imaging
agent may comprise magnetic material, such as iron oxide,
for magnetic resonance imaging. For optical imaging, the
45 active agent may be, for example, semiconductor nanocrys-
tal or quantum dot. For optical coherence tomography
imaging, the imaging agent may be metal, e.g., gold or
silver, nanocage particles. The imaging agent may be also an
ultrasound contrast agent, such as a micro or nanobubble or
50 iron oxide micro or nanoparticle.
Administration
The multistage delivery vehicle may be administered as a
part of a composition, that includes a plurality of the
vehicles, to a subject, such as human, via any suitable
55 administration method in order to treat, prevent and/or
monitor a physiological condition, such as a disease. The
particular method employed for a specific application is
determined by the attending physician. Typically, the com-
position may be administered by one of the following routes:
60 topical, parenteral, inhalation/pulmonary, oral, vaginal and
anal.
Embodiments of the multistage delivery vehicles may be
particularly useful for oncological applications, i.e. for treat-
ment and/or monitoring cancer or a condition, such as tumor
65 associated with cancer. For example, skin cancer may be
treated and/or monitored by topical application of, prefer-
ably, a viscous suspension; lung cancer may be treated
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and/or monitored by inhalation of an aerosolized aqueous
microdevice suspension; cervical cancer may be treated
and/or monitored by vaginal administration of a microdevice
suspension; and colon cancer may be treated and/or moni-
tored by rectal administration of such a suspension. The 5
majority of therapeutic applications may involve some type
of parenteral administration, which includes intravenous
(i.v.), intramuscular (i.m.) and subcutaneous (s.c.) injection.
Administration of the multistage delivery vehicles may be
systemic or local. The non-parenteral examples of admin-
istration 
l0
recited above, as well as i.m. and s.c. injections, are
examples of local administration. Intravascular administra-
tion may be either local or systemic. Local intravascular
delivery may be used to bring a therapeutic substance to the 15
vicinity of a known lesion by use of guided catheter system,
such as a CAT-scan guided catheter. General injection, such
as a bolus i.v. injection or continuous/trickle-feed i.v. infu-
sion are typically systemic.
For intravenous administration, the multistage delivery 20
vehicle may be formulated as a suspension that contains a
plurality of the vehicles. Preferably, the vehicles are uniform
in their dimensions and their content. To form the suspen-
sion, the vehicles as described above may be suspended in
any suitable aqueous carrier vehicle. A suitable pharmaceu- 25
tical carrier is one that is non-toxic to the recipient at the
dosages and concentrations employed and is compatible
with other ingredients in the formulation. Preparation of
suspension of microfabricated particles is disclosed, for
example, in US patent application publication No. 30
20030114366.
For oral administration, the multistage delivery vehicle
may administered as a part of an oral composition made up
of a plurality of the vehicles. Preferably, the vehicles in the 35
composition are uniform in dimensions, i.e. the first stage
particles of each vehicle have the same or substantially the
same dimension; the second stage particles of each vehicle
have the same or substantially the same dimensions. The
composition may be made by mixing the vehicles with 40
suitable non-aqueous carriers, such as oil or micronized
powder, and filled in unit dose amounts into standard
enteric-coated capsules or, alternatively, compressed into
tablets and coated with an enteric coating material. The
enteric coating ensures that the vehicles are transported in 45
dry form through the low (acidic) pH environment of the
stomach and released at pre-selected regions of the small or
large intestine.
The composition may be coated with a protective poly-
mer. This material may be applied by film coating technol- 50
ogy to either tablets or capsules to protect the product from
the effects of, or prevent release of drugs in, the gastric
environment. Such coatings are those, which remain intact
in the stomach, but may dissolve and release the contents of
the dosage form once it reaches the small intestine. The 55
purpose of an enteric coating may be to delay release of the
first stage particle's content.
One of the most extensively used enteric polymer may be
cellulose acetate phthalate (CAP). Another useful polymer
may be polyvinyl acetate phthalate (PVAP), which is less 60
permeable to moisture, more stable to hydrolysis and able to
ionize at a lower pH than is CAP. These properties may
allow more reliable release in the duodenum. Another
example of currently used polymers may be those based on
methacrylic acid-methacrylic acid ester copolymers with 65
acid ionizable groups. Represented among these are poly-
mers having the tradename Eudragit available through
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Rohm Pharma. Generally, the enteric coating may be applied
from about 0.5% by weight to about 10% by weight of the
tablet or capsule.
In some embodiments, a less water-soluble polymer, such
as methylcellulose, could be used to delay release of the
drug from the chambers following release of the particles in
the duodenum. ChronSetRTM technology developed by
ALZA Corporation (Mt. View, Calif.) may be used to release
a bolus of the multistage delivery vehicles at designated
times and at targeted sites after passage from the stomach
into the small intestine. In this case, a suspension of the
vehicles may be loaded into ChronSet capsules. After swal-
lowing, the capsules pass intact through the stomach. The
shell may be engineered to regulate the rate of water
imbibition the osmotically permeable portion of the system.
The osmotic engine may expand to push and separate two
halves of the capsule. The length of the capsule halves may
be specifically designed to produce separation at pre-se-
lected times. The contents of each capsule may be expelled
into the intestinal lumen at 2 to 20 hours after administra-
tion. Greater than 80% of contents (in this case a suspension
of drug-filled microfabricated particles) may be expelled
within 15 minutes time frame. This approach may provide a
means of releasing the suspension of the vehicles at prese-
lected areas of the small or large intestine. Such a system
may be used to release the multistage delivery vehicles at
sites in the small or large intestine that are optimal for
binding, such as areas, which contain receptors for the
muco-adhesive ligand grafted to the particles, and/or absorp-
tion, such as regions of the intestinal epithelium that are
sensitive to the permeation enhancers contained inside the
first stage particle.
Embodiments described herein are further illustrated by,
though in no way limited to, the following working
examples.
WORKING EXAMPLE 1
The following experiments were conducted to study load-
ing and release of selected second stage particles into
nanoporous silicon first stage microparticles. Biodegrada-
tion and biocompatibility of the nanoporous silicon first
stage particles was also studied.
Materials and Methods
Z2 Analysis
Particles were counted in a Z2 Coulter® Particle Counter
and Size Analyzer (Beckman Coulter). The aperture size
used for particle analysis was 50 µm. The lower and upper
size limits for analysis were set at 1.8 and 3.6 µm. For
analysis,particles were suspended in the balanced electrolyte
solution of the instrument (ISOTON® II Diluent) and
counted. The total volume of original suspension of particles
did not exceed 0.3% of the final analysis volume.
Oxidation of Silicon Microparticles
Silicon microparticles in IPA were dried in a glass beaker
kept on a hot plate (80-90° C.). Silicon particles were
oxidized in piranha (1 volume H2O2 and 2 volumes of
H2SO4). The particles sonicated after H2O2 addition and
then acid was added. The suspension was heated to 100-110°
C. for 2 hours with intermittent sonication to disperse the
particles. The suspension was then washed in DI water till
the pH of the suspension is —5.5-6. Particles were then
transferred to appropriate buffer, IPA or stored in water and
refrigerated till further use.
Surface Modification of Si Particles with APTES
Prior to the silanization process, the oxidized particles
were hydroxylated in 1.5 M HNO3 acid for approximately
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1.5 hours (room temperature). Particles were washed 3-5
times in DI water (washing includes suspending in water and
centrifuging, followed by the removal of supernatant and the
repeating of the procedure).
The particles were suspended in IPA (isopropyl alcohol)
by washing them in IPA twice. They were then suspended in
IPA containing 0.5% (v/v) of APTES (3-aminopropyltri-
ethoxysilane) for 45 minutes at room temperature. The
particles were then washed with IPA 4-6 times by centrifu-
gation and stored in IPA refrigerated. Alternatively, they
were aliquoted, dried and stored under vacuum and dessi-
cant till further use.
Attaching PEG to APTES Modified Particles
PEG was attached to the microparticles to provide a
spacer for further coupling with anti-VEGFR2 antibody.
Fmoc-PEG-NHS, which provided the NHS ester for rapid
coupling to amine groups and an Fmoc group to protect the
amine on the PEG, was useed. The 106-109 particles/ml of
APTES modified microparticles were resuspended in PBS
(pH-7.2) and Fmoc-PEG-NHS at a concentration of 1-10
mM added to the particles.
Coupling was carried out for 30 min to 1 h at room
temperature, then unreacted Fmoc-PEG-NHS groups were
washed by centrifugation 3-5 times in PBS. The Fmoc group
on the distal end of PEG coupled to the silicon micropar-
ticles were deprotected with piperidine (20% v/v for 30 min)
to provide a free amine on the PEG for further coupling with
antibodies.
Fluorescent Tagging of Anti-VEGFR2
The antibody to VEGFR2 was conjugated with Alexa 488
using an antibody labeling kit from Invitrogen Corp. The
fluorescent tag was conjugated to the antibody by following
the procedure provided in the manual of the kit. 1 mg/ml of
antibody was used for tagging. The amount of antibody
conjugated to the fluorescent tag was determined by ana-
lyzing the antibody with a DUO 730 UV/Vis Spectropho-
tometer (Beckman Coulter Inc., CA, USA) at 280 and 494
mu. The amount of antibody conjugated was found to be 407
µg/ml.
Coupling Anti-VEGFR2 to PEG Modified Particles
Silicon particles, resuspended in PBS, were treated with
the heterobifunctional crosslinker ANB-NOS (dissolved in
DMF and added to a final concentration of 10 mM) for 30
min to 1 h. The reaction was carried out in the dark to
prevent the photolysis of the nitrophenyl azide group on the
crosslinker The particles were then washed with PBS to
remove unreacted crosslinker and mixed with the fluores-
cently labeled anti-VEGFR2. 4.6x106 particles were used
for each experimental point. The different amounts of anti-
body used, were 0.814, 0.407, and 0.163 µg, corresponding
to 2.7, 1.35, and 0.54 µg/ml respectively, and exposed to UV
light for 10-15 min to couple the amine groups present on
the antibody to the attached crosslinker
Determining Buffer Cconcentration for Loading of Amino-
PEG Quantum-dots (Q-dots) into Porous Silicon Micropar-
ticles
In a low binding micro centrifuge tube, 3.0x105 large pore
(LP) and small pore (SP) oxidized silicon (stored at the
concentration of 300x106 particles/ml) or APTES modified
microparticles (stored at the concentration of 200x106 par-
ticles/ml), and 2µM Amino-PEG Q-dots or Carboxyl Q-dots
were combined in a solution containing 10, 20, 50, 100 or
200 mM of TRIS-HCl at pH 7.3. Samples were incubated in
a rotating wheel (20 rpm) for 15 minutes at 25° C. in a final
volume of 20 µl for each experimental point. After incuba-
tion, the samples were diluted with Tris 20 mM, pH 7.3 to
150 µl and promptly read at a FACScalibur flow cytometer
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for fluorescence intensity. FIG. 3, Panel A, presents results
of time dynamics for loading carboxy modified quantum
dots and amino modified quantum dots into APTES modi-
fied LP and SP silicon particles. FIG. 4, Panels A-D present
5 results of time dynamics for loading carboxy modified
quantum dots and amino modified dots into (Panel A) LP
oxidized silicon particles; (Panel B) LP APTES modified
silicon particles; (Panel C) SP oxidized silicon particles and
(Panel D) SP APTES modified silicon particles. Each of
to Panels A-D also presents time dynamics for loading PEG-
FITC single wall carbon nanotubes, as described below.
Determining Concentration of Amino-PEG and Carboxyl
Q-dots for Porous Silicon Microparticles Loading
15 In a low binding micro centrifuge tube, 3.0x105 LP or SP
oxidized silicon or APTES modified microparticles, were
combined with 0.01, 0.1, 1, 10, 100, 1000 and 2000 nM
Amino-PEG or Carboxyl Q-dots respectively, in 200 mM
TRIS-HCl pH 7.3. Samples were incubated in a rotating
20 wheel (20 rpm) for 15 minutes at 25° C. in a final volume
of 20 µl for each experimental point. After incubation, the
samples were diluted with Tris 20 mM, pH 7.3 to 150 µl and
promptly read at a FACScalibur flow cytometer for fluores-
cence intensity.
25 Determining Time for Loading ofAmino-PEG and Carboxyl
Q-dots into Porous Silicon Microparticles
In a low binding micro centrifuge tube, 1.2x106 LP and
SP oxidized silicon or APTES modified microparticles, were
combined with 2µM Amino-PEG Q-dots or Carboxyl
30 Q-dots in 200 mM TRIS-HCl pH 7.3 in a 80 µl final volume.
Particles and Q-dots were incubated in a rotating wheel (20
rpm) and sampled out from the vial after 15, 30, 45 and 60
minutes at 25° C. After incubation, the samples were diluted
with Tris 20 mM, pH 7.3 to 150 µl and promptly read at a
35 FACScalibur flow cytometer for fluorescence intensity.
Loading of Amino-PEG and of Carboxyl Q-dots into Oxi-
dized and APTES Modified Porous Silicon Microparticles
2.1x106 LP silicon microparticles either oxidized or
APTES modified were combined with 2µM Amino-PEG
40 Q-dots or Carboxyl Q-dots respectively, in a TRIS-HCl 200
mM pH7.3 solution. Final incubation volume was 140 µl.
Samples were incubated in a rotating wheel (20 rpm) for 15
minutes at 25° C. The microparticles were then washed in
1.4 mL deionized water (10 folds dilution), and centrifuged
45 5 minutes at 4200 RPM in a Beckman Coulter Allegra X-22
centrifuge. Particles pellet was resuspended in 70 µl of
deionized water and 10 µl were taken out the vial, diluted
with a TRIS 20 mM, pH 7.3 solution to 150 µl final volume.
Sample's fluorescence was immediately read with Becton
5o Dickinson FACScalibur flow cytometer and recorded as
time 0 or loading fluorescence.
Release of Amino-PEG and of Carboxyl Q-dots from Oxi-
dized and APTES Modified Porous Silicon Microparticles
The residual 60 µl were diluted 10 times into 600 µL of
55 TRIS-HCL 20 mM NaCl 0.9% release buffer. 100 µl were
taken out this solution and additionally diluted 5 times by
aliquoting the sample into tubes pre filled with 400 uL
TRIS-HCL 20mM NaCI 0.9% release buffer. Final dilution
at this point was 500 folds. Samples were put in a rotating
60 wheel (20 rpm) for the given amount of time (15, 45, 90,
180, 360 and 1200 minutes) minutes at 37° C. At each time
point the aliquots were centrifuged 5 minutes at 4200 RPM
in a Beckman Coulter Allegra X-22 centrifuge. Each pellet
was then resuspended in 150 µl of TRIS 20 mM and
65 fluorescence was immediately read with a Becton Dickinson
FACScalibur flow cytometer. FIG. 5A presents time dynam-
ics of release of amino-modified quantum dots from LP
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oxidized silicon particles. FIG. 5B presents time dynamics
of release of carboxy modified quantum dots from APTES
modified LP silicon particles.
Determining Buffer Concentration for Loading of Poly
(Ethylene Glycol) (PEG) Fluorescein Isothiocyanate (FITC)
Conjugated Single Walled Carbon Nanotubes (SWNTs) into
Porous Silicon Microparticles
In a low binding micro centrifuge tube, 3.0x105 large pore
oxidized silicon or APTES modified microparticles, were
combined with 20 ng/µl PEG-FITC-SWNTs in a solution
containing different molarities (20, 100, 200 mM) of TRIS-
HCl pH 7.3. Final volume was 20 µl for each experimental
point. Samples were incubated in a rotating wheel (20 rpm)
for 15 minutes at 25° C. After incubation, the samples were
resuspended in 150 µl of TRIS 20 mM and immediately read
at a FACScalibur flow cytometer for fluorescence intensity.
Determining Time for Loading of PEG-FITC-SWNTs into
Porous Silicon Microparticles
In a low binding micro centrifuge tube, 1.2x106 large pore
oxidized silicon or APTES modified microparticles, were
combined with 20 ng/µl PEG-FITC-SWNTs in 20 mM
TRIS-HCl pH 7.3 in a 80 µl final volume. Particles and
SWNTs were incubated in a rotating wheel (20 rpm) and
sampled out from the vial after 15, 30, 45 and 60 minutes at
25° C. After incubation, the samples were diluted with Tris
20mM, pH 7.3 to 150 µl and promptly read at a FACScalibur
flow cytometer for fluorescence intensity.
Determining Concentration of PEG-FITC-SWNTs for
Porous Silicon Microparticles Loading
In a low binding micro centrifuge tube, 3.0x105 LP or SP
oxidized silicon or APTES modified microparticles, were
combined with 1, 10, 20 and 50 ng/µl PEG-FITC-SWNTs in
20 mM TRIS-HCl pH 7.3 in a final volume of 20 µl for each
experimental point. After incubation, the samples were
diluted with Tris 20 mM, pH 7.3 to 150 µl and promptly read
at a FACScalibur flow cytometer for fluorescence intensity.
Determining Fluorescence Intensity and Quenching Effect
of PEG-FITC-SWNTs Using Fluorimetry
A concentration curve for PEG-FITC SWNTs in 20 mM
TRIS-HCL pH 7.3 was determined using a SPECTRAmax
fluorimeter. A serial dilution was performed, starting with 35
ng/µl and proceeding by a factor of 1:2 down to minimum
detectable amount of 107 pg/µl. The aliquots were placed in
a 96 well plate and the fluorescence was read using excita-
tion at 485, and emission at 520. Fluorescence quenching
was observed at the higher concentrations of SWNTs, as
shown by their lower fluorescence.
Loading of PEG-FITC-SWNTs into Oxidized and APTES
Modified Porous Silicon Microparticles
1.8x106 "large pore" (LP, approximately 30 mu) silicon
microparticles were combined with 20 ng/µl PEG-FITC-
SWNTs in a 20 mM TRIS-HC1 pH7.3 solution. Final incu-
bation volume was 120 µl. Samples were incubated in a
rotating wheel (20 rpm) for 15 minutes at 25° C. The
microparticles were then washed in 1.2 mL deionized water
(10 folds dilution), and centrifuged 5 minutes at 4200 RPM
in a Beckman Coulter Allegra X-22 centrifuge. After incu-
bation, the supernatants were removed and placed in a 96
well plate for fluorescence reading using the SPECTRAmax
plate reader.
Particles pellet was re-suspended in 60 µl of deionized
water and 10 µl were taken out the vial, diluted with a TRIS
20 mM, pH 7.3 solution to 150 µl final volume. Sample's
fluorescence was immediately read with Becton Dickinson
FACScalibur flow cytometer and recorded as time 0 or
loading fluorescence.
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Release of PEG-FITC-SWNTs from Oxidized and APTES
Modified Porous Silicon Microparticles
The residual 50 µl were diluted 10 times into 500 µL of
TRIS-HCL 20mM NaCl 0.9% release buffer. 100 µl were
5 taken out this solution and additionally diluted 5 times by
aliquoting the sample into tubes pre filled with 400 uL
TRIS-HCL 20 mM NaCl 0.9% release buffer. Final dilution
at this point was 500 folds. Samples were put in a rotating
wheel (20 rpm) for the given amount of time (15, 45, 120,
io 240 and 1200 minutes) minutes at 37° C. At each time point
the aliquots were centrifuged 5 minutes at 4200 RPM in a
Beckman Coulter Allegra X-22 centrifuge. The supernatants
were removed and placed in a 96 well plate for fluorescence
reading using the SPECTRAmax plate reader. Each pellet
15 was then resuspended in 150 µl of TRIS 20 mM and
fluorescence was promptly read with a Becton Dickinson
FACScalibur flow cytometer. FIG. 5A presents time dynam-
ics of release of PEG-FITC-SWNTs from LP oxidized
silicon particles. FIG. 5B presents time dynamics of release
20 of PEG-FITC-SWNTs from APTES modified LP silicon
particles.
Loading of Nanoliposomes into Oxidized andAPTES Modi-
fied Porous Silicon Microparticles
1.5x106 LP and SP oxidized silicon microparticles were
25 combined with 10 ng/µl of liposomes, containing an Alexa
fluo 555 conjugated siRNA, in a 20 mM TRIS-HCl pH7.3
solution. Particles and nanoliposomes were incubated in a
rotating wheel (20 rpm) and sampled out from the vial after
15, 30 and 60 minutes at 25° C. After incubation, the
30 samples were diluted with Tris 20 mM, pH 7.3 to 150 µl and
promptly read at a FACScalibur flow cytometer for fluores-
cence intensity.
Degradation
5x106 LP and SP oxidized silicon particles were either
35 mixed in a solution containing 2.5 mM TRIS and 0.9% NaCl
at pH 7.3 (Saline) or in cell culture media supplemented with
10% FBS (CCM). The mixture was incubated in a rotating
wheel (8 rpm) at 37° C. and sampling for SEM, Z2 and ICP
was performed at time 0 and after 6, 18 and 24 hours.
40 The experiment was designed in order to have enough
material to perform the three types of analysis for the
degradation study in parallel at the same time, thus avoiding
differences due to uncontrolled or unnoticed variables. This
protocol therefore applied to the samples obtained for SEM,
45 Z2 and ICP.
An additional degradation experiment was performed to
provide material for the toxicity experiment with HUVEC
cells. For each experimental point. we incubated 3x106 LP,
oxidized or Aptes modified, or SP, oxidized or Aptes modi-
50 fied, silicon particles in CCM in a rotating wheel (8 rpm) at
37° C. for 24.
ICP
To understand whether the porous Silicon particles dis-
appeared from the solutions, they were incubated in, the
55 porous Silicon particles were dissolved in Silicic Acid and
studied by a technique called Inductive Coupled Plasma
Atomic Emission Spectrometry (ICP-AES).
This methodology allows quantifying the absolute
amount of any given element present in a solution. Amples
60 were withdrawn at the same time points, the Z2 and the SEM
analysis and centrifuged them to pellet down the particles
that were not degraded yet. The surnatants filtered through
a 0.450 µm filter unit were analyzed with ICP.
Cell Culture
65 Half a million freshly isolated Human Umbelical Vein
Endothelial Cells (HUVEC) (CloneticsTM Cambrex Bio Sci-
ence Walkersville, Inc) were plated in M199 medium
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(Gibco/Life Technologies Inc.) supplemented with 10%
foetal calf serum (FCS, Gibco), containing 100 IU/ml peni-
cillin (Sigma), 100 g/ml streptomycin (Sigma), 7.5 IU/ml
heparin (Sigma), 2 ng/ml epidermal growth factor (EGF)
(R&D system) and 250 pg/ml endothelial cell growth factor
(-ECGF) (BioSource, USA), referred to as complete
medium. Confluent cells were detached with trypsin (Sigma)
for subculturing. The cells were expanded until passage 6
and used for the biocompatibility studies.
Microscopy
Cells were analyzed in bright field contrast with an
Olympus CKX41 microscope with a 40x magnification lens.
Images were taken with an SP-350 Olympus True-Pic
TURBO Image Processor camera.
LDH Toxicity Assay
For the calibration of the toxicity assay, different amount
of cells (125, 250, 500, 1000, 2000) were seeded in three 96
well plates. After 12, 24 and 48 hours the cell culture media
was replaced with fresh media containing 1% Triton. The
cells were incubated at room temperature (RT) for 10
minutes then spun down for 3 minutes at 1200 rpm and 100
µl of cell culture media were transferred into a replica plate
kept on ice. 100 µl of a solution containing the reconstituted
catalyst and the dye (Biovision LDH Cytotoxicity Assay
Kit) was added to each well and the plate was transferred on
an orbital shaker, covered with foil and shaked at RT for 20
minutes. The plate was then transferred in a SPECTRAmax
fluorimeter and absorbance at 490 mn was read. All the
experiments were done in triplicate and results expressed as
mean values with standard deviations.
For the experiment, 1000 cells were seeded and, after the
cells attached on the surface (approximately 6 hours), dif-
ferent amount of LP oxidized, SP oxidized, LP APTES and
SP APTES Silicon particles (1000, 5000 and 10000, corre-
sponding to a 1:1, 1:5, 1:10 cells: particles ratio) resuspended
in 2µl of sterile, deionized H2O were added to the media. As
a positive control, 2µl of sterile, deionized H2O were added
to the cells while as a negative control we added 50 µg/ml
of Cis-platinum to cell culture media.
The plates were incubated at 37° C. and, at the time points
of 12, 24, 48 and 72 hours, the toxicity assay was performed
as described for the calibration assay with the exception of
Triton addition. All the experiments were done in triplicate
and results expressed as mean values with standard devia-
tions.
MTT Assay
For the calibration of the MTT assay, different amount of
cells (125, 250, 500, 1000, 2000) were seeded in three 96
well plates. After 12, 24 and 48 hours the cell culture media
was replaced with fresh media containing 50 µl of MTT dye.
The cells were incubated at 37° C. for 4 hours then the media
and MTT were removed and 200 µl of DMSO and 25 µl of
a 0.1M glycine, 0.1 M NaCl, pH 10.5, solution were added
to each well and the plate was incubated at RT for 10
minutes. The plate was then transferred in a SPECTRAmax
fluorimeter and absorbance at 570 mn was read. All the
experiments were done in triplicate and results expressed as
mean values with standard deviations.
For the experiment 1000 cells were seeded and, after the
cells attached on the surface and generated a 50% confluent
cell bed (approximately 6 hours), different amount of LP
oxidized, SP oxidized, LP APTES and SP APTES Silicon
particles (1000, 5000 and 10000, corresponding to a 1:1, 1:5,
1:10 cells:particles ratio) resuspended in 2 gl of sterile,
deionized H2O were added to the media. As a positive
control, 2µl of sterile, deionized H2O were added to the cells
30
while as a negative control we added 50 µg/ml of Cis-
platinum to cell culture media.
The plates were incubated at 37° C. and, at the time points
of 12, 24, 48 and 72 hours, the medium was removed from
5 the well and the cells extensively washed with sterile PBS to
remove Silicon particles. The proliferation assay was then
performed as described for the calibration assay. All the
experiments were done in triplicate and results expressed as
mean values with standard deviations.
10 Propidium Iodide Staining
0.6x106 cells were seeded in 25 cm2 flasks and when the
cells were attached (approximately 6 hours later, when the
cells generated a 60% confluent cell bed), 3x106 of either LP
15 oxidized, SP oxidized, LP APTES or SP APTES Silicon
particles (1:5 ratio) resuspended in 20 µl of sterile, deionized
H2O, were added to the medium of each flask. As a positive
control 20 µl of sterile, deionized H2O were added to the
cells while as a negative control we added 50 µg/ml of
20 Cis-platinum to cell culture media. As an additional control,
the same amount of HUVEC cells was seeded in 75 cm2
flasks to allow them to freely grow without reaching con-
fluency during the experiment.
After 12, 24, 48 and 72 hours cells were washed 3 times
25 with 5 ml of sterile PBS then were trypsinized, harvested
and centrifuged. After an additional washing step with PBS,
each cell pellet was resuspended in 250 µl of PBS and 750
µl of ice-cold methanol were added to cell suspensions while
gently vortexing. Fixation was carried on for 20 minutes
30 then the cells were spun down and washed twice with PBS.
A solution containing (50 µg/ml propidium iodide in 10 mM
Tris, 5 MM MgC12, pH 7.3 and 75 µg/ml RNAse) was then
added to the cell pellet and the suspension was incubated in
dark on a rotating wheel (5 rpm) for 60 minutes. Samples
35 were then transferred into FACS tubes and immediately read
with a Becton Dickinson flow cytometer.
Flow Cytometry Setup
Particles were assessed for fluorescence using a FACS
Calibur (Becton Dickinson). Bivariate dot-plots defining log
40 SSC versus log FSC were used to evaluate the size and shape
of the Silicon particles (3 microns in diameter, 1.5 in height)
used and to exclude from the analysis non-specific events.
Control rainbow BD CalibriteTM beads (3.5 micron in size)
were analyzed as a standard.
45 Apolygonal region (R1) was defined around the centre of
the population excluding the events that were to close to the
noise signal of the instrument. For each sample, the number
of particles detected in the RI region was above 80%.
For mean fluorescence intensity (MFI) determination, log
5o FLl and FL2 versus log FSC dot-plots were created by
gating on the events falling within the defined region (RI).
The peaks generated by each of the samples were analyzed
in the corresponding fluorescent histogram and the geomet-
ric mean values recorded.
55 For particles detection, detectors used were forward scat-
ter (FSC) E-1 and side scatter (SSC) with 474V voltage set.
The fluorescent detector FLl was set at 800V.
Green fluorescence (FITC and Q-dots525) was detected
using FLl, 530/30 mn band-pass filter. Orange and red
60 fluorescence (Q-dots D565 and Propidium Iodide) was
detected using FL2. As single color detection only was being
analyzed compensation was set at zero. Instrument calibra-
tion was carried out before, in between and after each series
of acquisition using rainbow BD Calibrite m beads.
65 For cells detection, detectors used were linear forward
scatter (FSC) E00 with an amplification gain of 4.59 and
linear side scatter (SSC) with the voltage set at 474V with
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an amplification gain of 1.07. The fluorescent detectors FL2
was set at 449V with the amplification gain set at 1.32.
Cell and particle debris were electronically gated from the
analysis on basis of scatter properties. In all the experiments
at least 20,000 particles or cells were analyzed. All the
experiments were performed in triplicate. The results are
presented as mean fluorescence intensity of intact particles
or viable cells only. Data analysis was carried out with
CellQuest software (BD Biosciences).
Fluorescent Microscopy
Fluorescent imaging of particles was performed with a
Nikon Eclipse TE2000-E with a DQC-FS Nikon CCD
Camera kept at —30.1° C. All the samples were mounted
immediately before the analysis and the images acquired
with a 63x immersion oil objective. The microscope settings
were kept constant throughout all the experiments. Numeri-
cal Aperture was set at 1.4, Refractive Index at 1.515,
Exposure Time at 500 ms, Readout Speed at 10 MHz and
Conversion Gain at 1/6x. The images were analyzed and
measured with the NIS Elements AR 2.3 Software.
Results
Antibody Conjugation
The total number of particles used for conjugating APTES
modified particles with the anti-VEGFR2 was —7.03x106.
Two different amounts of anti-VEGFR2 were used for the
conjugation as listed in Table 3 below.
TABLE 3
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TABLE 5-continued
Zeta Potential of microparticles and
nanoparticles used in loading experiments
5 Size of Zeta potential Buffer conidition
Particle nanopores (nn) (mV) at pH-7.3
LP MPTMS modified Si 20-40 —16.9 20 mM Tris
—6.17 200 mM Tris
SP oxidized Si 5-7 —11.15 20 mM Tris
10 —13 200 mM Tris
SP APTES modified Si 5-7 6.42 20 mM Tris
—7.42 200 mM Tris
SP MPTMS modified Si 5-7 —18.3 20 mM Tris
—8.21 200 mM Tris
Amino gDots NA —1.21 20 mM Tris
15 1.3 200 mM Tris
Carboxy gDots NA —32.8 20 mM Tris
—10.1 200 mM Tris
SWNTs NA —9.21 20 mM Tris
20
25
Amount of anti-VEGFR2 added to particles
Anti-VEGFR2 Anti-VEGFR2 per 106 30
Particles ID added (µg) particles (µg)
APTES 1 2.04 0.29
APTES2 0.407 0.058
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In a different experiment, after conjugation, the particles
were washed and centrifuged in phosphate buffer containing
0.5% Triton X-100 6 times followed by 4 washes in plain
phosphate buffer and then read on the plate reader. Two
different amounts of anti-VEGFR2 were used for the con-
jugation as listed in Table 4 below.
TABLE 4
Amount of anti-VEGFR2 conjugated to particles as detected by
plate reader based on fluorescence assay of the anti-VEGFR2. 45
Particles No. of Amt. of Anti-VEGFR2 Anti-VEGFR2 per
ID particles (µg) 106 particles (µg)
APTES1 7.42 x 105 0.065 0.088
APTES2 7.42 x 105 0.022 0.03 
50
As indicated by Table 4, there was a significant reduction
in the number of particles in all the cases during the
conjugation. This might be due to losses incurred during the
numerous washing steps involved in removing unbound 55
antibody from the solution.
TABLE 5
Zeta Potential of microparticles and
nanoparticles used in loading experiments
Size of Zeta potential Buffer conidition
Particle nanopores (nn) (mV) at pH-7.3
LP oxidized Si 20-40 —10.1 20 mM Tris
1.31 200 mM Tris
LP APTES modified Si 20-40 6.52 20 mM Tris
5.19 200 mM Tris
Load and Release
Quantum dots (Qdots) and single-wall carbon nanotubes
(SWNT) were used as second stage nanovectors for their
distinct and excellent properties. Q-dots are light-emitting
semiconductor nanocrystal (CdSe or CdTe), and many
research has been conducted on in-vitro and in-vivo molecu-
lar and cellular imaging because of their high brightness,
photostability and the capacity of multiplexed color coding.
Q-dots were coated with hydrophilic polyethylene glycol
(PEG) to increase biocompability. The zeta potential was
-1mV for Amino-PEG Qdots in 20 mM Trs buffer, and —32.8
mV for carboxyl PEG Q-dots. The hydrodynamic size was
measured by the diffusion coefficient of colloidals in solu-
tion using scattering light dynamic light scattering tech-
nique. Amino and Carboxyl Q-dots show similar hydrody-
namics size (13 and 17 nm respectively).
SWNT is well-ordered hollow "rolled-up" structures, and
has high aspect ratio, high surface area, high mechanical
strength, ultra light weight, excellent chemical/thermal sta-
bility. Many protocols have been studied to functionalize the
SWNT surface with peptides, proteins and drugs. In this
study, SWNT was of diameter 2-4 nun and lengths between
30 and 100 mu, the surface was functionalized with PEG-
amine, providing solubility in water and physiological saline
and further linked to FITC for fluorescent imaging. The zeta
potential measurement shows —9.2 mV in 20 nM TRIS
buffer.
The effect of Tris concentration on the loading of quantum
dots in large pores particles was first investigated. Tris was
selected as a buffering agent because, it may give the highest
stability to the quantum dots (Q-dots) compared to other
buffering agents. The mean fluorescence of Q-dots loaded
particles was studied as a function of Tris concentration. The
fluorescence signal on the particles increased as the Tris
concentration increases. The concentration of 200 mM Tris
gave the best effect in terms of loading and was therefore
selected for all the subsequent experiments.
The loading capacity of "large porous" silicon particles
was evaluated by using "small porous" silicon particles as
the control. The hydrodynamic size of Q-dots is 13-15 mu,
and should not be able to get into the small pores (<5 mu)
but stay on their surface. The concentration effect of Q-dots
for the loading was performed by changing the amount of
Q-dots from 10 picomolar to 2 micromolar and incubating
all the reactions in the same final volume (20 µl ). Sample's
loading was analyzed at FACS and the quantum dot con-
centration of 2µM resulted in the highest level of loading
and therefore used for all the subsequent experiments.
The loading time/dynamics of particles with Q-dots were
studied by different incubation time (15 min, 30 min and 60
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min). The loading of Q-dots in the particles was a very fast
process that reached its maximum within 15 min. After that,
the fluorescence signal drops slowly with time as shown in
FIG. 21, Panels a-d.
The surface properties of particles also proved to be
important in the loading kinetics. As shown in FIG. 21,
Panels a-d, carboxyl PEG Q-dots showed little loading into
the oxidized particles. This may be attributed to the elec-
trostatic force since both particles were negatively charged.
When the surface of the silicon particles was modified with
amino groups (APTES), the zeta potential became positive
(+5—+6 mV) as shown in Table 5. The loading of carboxyl
Q-dots significantly increased into APTES treated particles.
The charge of amino-PEG Q-dots is almost neutral (zeta
potential —1—+1 mV), and the APTES treatment of silicon
particles had only a minor impact on the loading (zeta
potential changed from —11 mV to +6 mV).
The kinetics of amino quantum dots release from LP
oxidized particles were exponential like with a 33%
decrease of the amount of loaded nanoparticles after 20
minutes and of 67.5% after 45 minutes. After 20 hours only
a residual 1% of the initial fluorescence was found associ-
ated to the particles demonstrating that all the quantum dots
could be released from the nanoporous silicon particles.
Fluorescence Quenching
The fluorescence of a solution containing 35 µg/ml of
FITC conjugated single wall carbon nanotubes (FITC-
SWNTs) and of a serial dilution of them (ranging from 1:2
to 1:2048) in milliq pure water was measured (FIG. 6A,
Panel A). The fluorescence values of the first 3 and more
concentrated samples (respectively 35, 17.5 and 8.725
µg/ml) were lower than the values of less concentrated
solution. This is a phenomenon known as fluorescence
quenching. As a control the same readings were performed
with a series of solutions of carboxy pegylated quantum dots
ranging from 8µM to 4 nM that showed a linear decrease of
the fluorescence value along with the dilution. The fluores-
cence quenching dynamics in the loading of APTES modi-
fied LP particles with FITC-SWNTs was evaluated. The
experiments were performed as previously described. The
profiles of the curves suggested that the loading of the higher
amount of FITC-SWNTs induced fluorescence quenching
thus resulting in decreased fluorescence of the silicon par-
ticles. The concentration of 20 µg/ml was selected for all the
subsequent experiments (FIG. 6A, Panel B and FIG. 20,
Panel B).
The effect of Tris concentration on the loading of PEG-
FITC-SWNTs and q-dots in large pores particles was also
investigated, see FIG. 613, Panels C-F. Panel E and Panel F
show the mean fluorescence of PEG-FITC-SWNTs loaded
particles in LP APTES modified and LP oxidized silicon
particles as a function of Tris concentration. The fluores-
cence signal on the particles decreased as the Tris concen-
tration increased. The concentration of 20 mM Tris gave the
best effect in terms of loading and was therefore selected for
all the subsequent experiments.
Carbon Nanotubes Loading
The dynamics of the loading of both oxidized and APTES
modified LP and SP particles with FITC-SWNTs was evalu-
ated. The experiments were performed as previously
described using 20 µg/ml of fluorescent nanoparticles (see
FIG. 4, Panels A-D). In this experimental setting, the loading
time dynamics were fast for the LP APTES particles that
showed a similar decrease at later time points (FIG. 4, Panel
B, and FIG. 21). A different kinetic was observed for the LP
oxidized particles loading that increased during the whole
0_1
duration of the experiment and reached its maximum at the
60 minutes time point (FIG. 4, Panel A, and FIG. 21).
The same loading patterns were occurring during the
loading of small pore particles (SP). The APTES modified
5 particles loaded very quickly and then lost some of their
associated fluorescence through time (FIG. 4, Panel D, and
FIG. 21), while the oxidized SP loading increased over time
as happened with the LP particles suggesting that APTES
modification played a crucial role in the loading process
io (FIG. 4, Panel C, and FIG. 21).
The kinetics of PEG-FITC-SWNTs release from LP oxi-
dized particles were exponential like in the first time points.
The release slowed down in later time points. After 20 hours
only a residual 20% of the initial fluorescence was found
15 associated to the particles suggesting that some of the
payload could be retained into the nanoporous silicon par-
ticles (FIG. 7B and FIG. 21)
Nanoliposomes also loaded into LP particles with the
same dynamics as described above. The fluorescence asso-
20 ciated with the Silicon particles were visualized by means of
fluorescence microscopy (FIG. 8A, Panels A and B, FIG. 813,
Panels E and F).
Degradation
Porous Silicon (PSi) is known to be fully biodegradable
25 (Mayne 2000; Low, Williams et al. 2006) and biocompatible
(Canham 1995). The oxidation process, that was performed
according with protocols already described for Silicon
wafers (Canham 1997), introduced hydroxil groups (OH) on
the exposed Silicon surface and these groups, in the presence
30 of water, are subjected to hydrolysis thus converting solid
Silicon into highly soluble Silicic acid.
SEM
The study of the modifications in the size, shape and
overall aspect of the particles was performed by Scanning
35 Electron Microscopy (SEM) (FIGS. 9 and 10). The images
showed that the particles degraded along time starting from
the areas with high porosity and then degradation spread to
particles edges where the porosity is lower and the size of
the pores smaller. It is suprising to notice that the overall
40 shape of the particles remained almost intact until the end of
the degradation process occurred. Although the present
inventions arenot limited by a theory of their operation, this
surprising observation may be explained by the fact that
corrosion of oxidized Silicon surfaces progressively con-
45 sumed the walls in between the pores thus creating bugs and
holes in the center of the particles. The same process took
more time to dissolve the sides of the particles, where the
number of pores is smaller and the walls between the pores
are thicker.
50 Z2 Coulter
The characterization of nanoporous Silicon particles deg-
radation was performed through several techniques. The
measurement of a decrease in the number of particles and in
their volume was performed with Z2 Coulter® Particle
55 Counter and Size Analyzer (Beckman Coulter). The par-
ticles were kept for 24 hours in a rotating wheel (8 rpm) at
37° C. in two different solution: TRIS 2.5 mM, 0.9% NaCl
at pH7.3 (Saline) and Cell Culture Media with 10% FBS
(CCM). To understand, if the size of the pores had a role in
60 the degradation kinetics, both Silicon particles with smaller
pores of 7-10 (SP) nanometers and particles with larger
pores of 20-30 nanometers (LP) were used.
The particles incubated in Saline did not show any
significant decrease in their median size distribution, either
65 in the case of LP and in the SP. On the contrary, their number
went progressively down throughout time (FIG. 11, Panel
A). These results combined together may mean an overall
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loss of Silicon particles mass of 50% or more for both LP
and SP particles at 24hrs, as indicated in FIG. 11, Panel C.
In the experiment performed with particles incubated in
CCM, a decrease in both their median size and number (FIG.
11, Panel B). These results combined together indicated a
loss of particles mass of 60% for the LP particles and more
than 90% for SP particles.
ICP
The readings at the ICP showed a linear increase in the
amount of silicon present after degradation. These data
confirmed the ability of the ICP-AES method for verification
of degradation. The data were regular, with low standard
deviations, and had a strong correlation with the Z2 readings
of particles count and size during the test. The increased
degradation that occurred in cell culture media as opposed to
TRIS buffer suggested high biodegradability of these par-
ticles in cell culture conditions (FIG. 12A, Panels A-B and
FIG. 12B, Panels C-D).
Biocompatbility
Silicon nanoporous particles induced cell toxicity by
means of Lactate Dehydrogenase (LDH) toxicity assay
(Biovision Inc.), cell proliferation by means of MTT assay
(Promega) and apoptosis and cell cycle by means of Pro-
pidium Iodide staining.
Bright Field Microscopy
Cells grown in the presence of porous Silicon particles did
not show any significant or abnormal type of morphological
change (FIG. 13, Panels A-D) during time. The cells were at
50% confluency after 12 hours and they reached almost
100% confluency after 24 hours. Some signs of apoptosis or,
more generally, of cell death were visible at 48 hours and
even more at 72 hours (bright, rounded, reflectant cells or
cells with large, multilobular nuclei or with high narrowing
of the cell body) as indicated by the white arrows in the FIG.
13, Panels A-D. This was mainly due to the fact that the cells
had already reached confluency and could not find any space
to grow further and thus underwent some processes of cell
degradation.
LDH Toxicity Assay
LDH is a cytoplasmic enzyme that is released into the
cytoplasm upon cell lysis. The LDH assay, therefore, is a
measure of membrane integrity. The basis of the LDH assay
are oxidization of lactate to pyruvate by LDH, pyruvate
reaction with the tetrazolium salt to form formazan, and the
spectrophotometrical detection of the water-soluble forma-
zan. (Decker, T. & Lohmann Matthes, M. L. (1988) J.
Immunol Methods 15:61-69; Korzeniewski, C. & Calle-
waert, D. M. (1983) J. Immunol Methods 64:313-320).
A toxicity calibration curve (FIG. 14A, Panel A) was
made to correlate the absorbance values read at fluorimeter
with the number of cells that were lysed by 1% Triton
incubation. From this calibration curve, the amount of cells
that were releasing the LDH enzyme during particles incu-
bation was derived. At 12 and 24 hours, the toxicity signal
was very low and could be mainly due to unbound cells that
did not recover from trypsinization and seeding (background
toxicity). This was confirmed by comparing the toxicity
values coming from the experimental plates with those
measured in the control plates (FIG. 14A, Panel B). The
toxicity of HUVEC cells grown in the 96 well plates without
any particles (positive control) showed at 72 hours a mean
absorbance of 0.496 at 470nm. That was almost the same
value as from cells incubated with a 1:1 ratio (0.507). At the
higher cells:particles ratios (1:5 and 1:10) the mean values
for toxicity were 0.55 and 0.57 respectively (FIG. 14A,
Panel B and FIG. 14B, Panels C-F). The same toxicity
pattern was observed in all the experimental conditions thus
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showing that porosity and surface chemistry did not either
increased or decreased cell toxicity. All together these results
did not suggest any massive toxicity due to exposition of
cells to particles.
5 MTT Proliferation Assay
MTT is a yellow water-soluble tetrazolium dye that is
reduced by live cells to a water insoluble purple formazan.
The amount of formazan may be determined by solubilizing
it in DMSO and measuring it spectrophotometrically. Com-
io parisons between the spectra of treated and untreated cells
may give a relative estimation of cytotoxicity. (Alley et al.
(1988) Cancer Res. 48:589-601). A toxicity calibration curve
(FIG. 15, Panel A) to correlate the absorbance values read at
fluorimeter with the number of growing cells. From this
15 calibration curve, the amount of cells that were metaboli-
cally active was derived.
At 12, 24 and 48 hours, the proliferation of cells incubated
with particles was exactly the same that in the control plate
(FIG. 15, Panel B). At 72 hours the mean absorbance at 570
20 mu was 1.635 for HUVEC cells cultured without any
particles (positive control) while it was 1.623 from cells
incubated with a 1:1 ratio. At higher cells: particles ratios
(1:5 and 1:10) HUVEC gave an absorbance value equal to
1.46 and 1.41 respectively (FIG. 15, Panels B-F). These
25 lower values correlated with a slight decreased in cell
proliferation when the cells were cultured in presence of a
high number of particles. This was in accordance with the
little increase in toxicity measured with the LDH assay at 72
hours (FIG. 14A, Panel B and FIG. 14B, Panels C-F).
30 The same proliferation pattern was observed in all the
experimental conditions thus showing that porosity and
surface chemistry did not either increased or decreased cell
growth. All together these results did not suggest any
significant change in cell viability due to exposition of cells
35 to particles.
Cell Cycle and Apoptosis
HUVEC cells exposed for 12, 24, 48 and 72 hours to a 1:5
ratio of particles (LP and SP either oxidized or APTES
modified) were analyzed after fixation and propidium iodide
40 staining at FACS. The forward scattering (FSC) and side
scattering (SSC) in a dot plot and in a contour plot were first
analyzed (FIGS. 16A-1-FIGS. 16C-3, Panels A-C). FSC
parameter provided an information of the size of the cells
while SSC provided an information of the shape of the cells.
45 The 3D plot on the bottom of each panel indicated on the
z-axis the counts or events and provided an information on
the overall distribution of the cells analyzed at FACS.
The peaks of necrotic/apoptotic cells that were character-
ized by a smaller and less homogeneous shape are indicated
50 with the red arrows. The data reported in FIGS. 16A-1-
FIGS. 16C-3, Panels A-C, are relative to HUVEC cells
incubated with Saline (control) and with LP and SP oxidized
Silicon particles. Cells distribution along time changed
significantly, with a major accumulation in the low SSC, low
55 FSC region at 48 and 72 hours. No significant difference in
the distribution of cells among the 3 groups was noticed and
the same results were obtained from the cells treated with LP
and SP APTES modified particles. Although the present
inventions are not bound by their theory of operation, the
60 induction of cell death at later time points could be attributed
to overconfluency. This could be expected since the seeded
cells were at 60% confluency at day 0 in order to keep the
experiment as close as possible to a physiologic solution, in
which the particles would contact the endothelial walls of
65 capillaries.
The distribution of the treated HUVEC cells in the
different phases of the cell cycle was also measured quan-
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titatively (FIG. 17A-17D). By comparing the data coming
from control cells (FIGS. 16A-1-FIGS. 16C-3, Panel A,
HUVEC+Saline) with the ones coming from LP and SP
treated cells it was confirmed that exposure to Nanoporous
Silicon Particles was not toxic and did not induce any
significant increase in the amount of cell death. It was also
demonstrated that there were no alterations in the cell cycle
phases between treated and untreated cells.
In order to demonstrate that not only the intact particles,
but also their degradation products did not induce any
toxicity, HUVEC cells were incubated with CCM containing
the degradation product of all the particles type and con-
firmed the results described so far (FIG. 17D). A slight
increase was measured in the amount of cells in the apop-
totic region when the cells were incubated for 72 hours with
the degradation product of SP oxidized and SP and LP
APTES modified particles. It may be possible that smaller
Silicon fragments produced during the degradation process
induced some kind of toxicity45-4a
WORKING EXAMPLE 2
A multi-stage delivery system based on biodegradable
silicon particles containing nanopores of specific size as first
stage carriers that may load, carry, release and deliver into
cells multiple types of nanoparticles with a precise control
was developed. The first stage silicon nanoporous particles
may be simultaneously loaded with different types of second
stage nanoparticles, which are released in a sustained fash-
ion over time. The major physical, chemical, and electro-
static mechanisms that control the loading and release of
second stage nanoparticles were defined. Finally, it was
shown that the porous silicon carriers are able to locally
delivery the second stage nanoparticles into the cytoplasm.
Taken together, these studies provide evidence that silicon
nanoporous particles may be used as cargoes for the simul-
taneous deliver of different types of nanovectors into cells.
This system may offer unprecedented methods to achieve
intracellular delivery of multiple therapeutics and/or imag-
ing agents.
Introduction
Since its development in the last decade, nanotechnology
has being used in a wide variety of applications in biomedi-
cal research for disease detection, diagnosis, and
treatment' -3. The objectives of many studies involving the
development and refinement of nanoparticles have focused
on their use as agents for delivery of therapeutic or imaging
molecules to organs, tissues, and cells4°5. A number of
different nanovectors have been evaluated for therapeutic
uses, including liposomes of various sizes and composi-
tion 6,7 ,  quantum dots (Q-dots)$°9, iron oxide10, single wall
carbon nanotubes (SWNTs)11, gold nanoshells12,13and sev-
eral other types of nanoparticles 14. The progress thus far has
given rise to the field defined as "molecularly targeted
therapeutics" 15-1a however the accomplishment of the
original objective, which is to selectively deliver a thera-
peutic agent using a nanovector-based delivery system, has
not been fully realized19,20
The integration of nanovectors into nanoporous silicon
particles may allow the nanovectors to evade the natural
biological barriers that may normally retard their therapeutic
effects. Such approach may provide protection of therapeu-
tic agents from surrounding fluids and molecules that may
normally degrade them prematurely and from uptake by the
Reticulo Endothelial System (RES). This may lead to a
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greater stability of the active agents, while providing
increased delivery and concentrated dosage of therapeutic
agents to a targeted tissue.
The multiple and simultaneous loading of second stage
5 nanoparticles into first stage silicon nanoporous particles
was achieved. The second stage particles (Q-dots and
SWNTs) were slowly released over time periods sufficient
for the first stage particle to reach a specific biological target
site. The main physical, chemical and electrostatic mecha-
nisms that govern the loading and release processes were.
The nanodelivery system was able to locally release its
payload into cells.
Results
15 First and Second Stage Particles
Silicon microparticles were characterized by Z2 Coulter®
Particle Counter and Size Analyzer to measure their volume,
size and concentration and by Scanning Electron Micros-
copy (SEM) to evaluate their morphology in detail. FIG. 19,
20 Panels a and b, show representative SEM images of the back
and front sides and of the cross sections of "large pore" (LP)
and "small pore" (SP) silicon particles respectively. These
particles are highly porous and hemispherical in shape. The
diameter of LP particles is approximately 3.5 µm, with pores
25 of straight profile, which cross the particles perpendicularly
to their external surface and have pore size ranging from 20
to 30 nm (FIG. 19, Panel a). SP silicon particles have a mean
diameter of 3.2 µm, and have a flatter shape than LP silicon
particles as a consequence of anodization and electropolish-
30 ing processes used to produce them, with pore sizes less than
10 nm (FIG. 19, Panel b). Both LP and SP silicon particles
have a thickness of 0.5-0.6 µm. According to BET analysis,
the surface area is 156 m2 g-1 for LP particles and 294 m2
35
 
g-'for SP particles. Pore volume is 0.542 cm3 g 1 for LP
particles and 0.383 cm3 g-1 for SP particles. The pore
density, size, shape and profile may be finely tuned by
changing electrical current, etching time, and doping, which
is reproducible from batch to batch. Non-oxidized silicon is
40 a hydrophobic material but a variety of surface treatment
protocols are available for silicon-based materials to be
stabilized and further functionalized with oligonucle-
otides27, biomolecules28, antibodies29'30, and polyethylene
glycol (PEG) chains31. Oxidized silicon particles have a
45 negative zeta potential value (-10.1 for LP; -11-25 for SP)
due to the presence of the hydroxyl groups on the surface of
the particles32. The particles that were modified with APTES
have a positive zeta potential value (6.52 for LP; 6.45 for
SP) as a consequence of the introduction of amino groups on
50 their surface. The hydrodynamic size of Q-dots was mea-
sured by the diffusion coefficient of colloidal in solution
using dynamic light scattering technique. Diameter was 13
mu for Amino-PEG Q-dots, and 16 mu for Carboxyl Q-dots.
Size of PEG-FITC-SWNTs was evaluated by AFM micros-
55 copy. The diameter of non PEGylated SWNTs is around 1
mu but due to the PEG surrounding the nanotubes, PEG-
FITC-SWNTs used for this study had a mean diameter of 4
mu, and a mean length of 30 mu. The SWNTs were
functionalized using PEG-amine through carboxylic acids
60 obtained via the SWNT cutting process and were conjugated
to FITC to allow for their fluorescent imaging. Second stage
nanoparticles with fluorescent properties were selected to
quantify loading into and release from silicon nanoporous
particles using established techniques, such as flow cytom-
65 etry, fluorimetry, as well as both fluorescence and confocal
microscopy. Physical and chemical of first and second stage
particles are summarized in Table 6.
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TABLE 6
Chemical Pore Zeta
I" Stage Particle Modification size, nm potential, mV
"Large pore" (LP) oxidized 20-40 —10.1
LP APTES 20-40 6.52
"Small pore" (SP) oxidized 5-7 —11.15
SP APTES 5-7 6.42
2"d Stage Particle Size, nm
10
Q-dots Amino PEG 13 —1.21
Q-dots Carboxyl PEG 16 —32.8
SWNTs PEG-FITC Diameter 4 —9.21
Length 30
Loading Second Stage Nanoparticles into First Stage Silicon 15
Particles
Protocols to efficiently load nanoparticles inside the pores
of first stage silicon particles were developed. One of the
factors affecting the loading process was the amount of 20
second stage particles in the media surrounding the particles.
The analyzed fluorescent intensity of silicon particles loaded
with increasing amounts of both Q-dots (FIG. 20, Panel A)
and PEG-FITC-SWNTs (FIG. 20, Panel B) and demon-
strated that particles loading was directly correlated with the 25
second stage particles concentration. By raising the concen-
tration of the second stage particles, progressively higher
levels of loading were achieved as assessed by flow cytom-
etry (FIG. 20, Panels A and B) and by direct visualization
with fluorescent microscopy (FIG. 20, Panels C and D). 30
These studies also demonstrated that surface chemical
properties of both the first stage silicon particles and second
stage particles affected loading efficiency and stability of the
assembled multi-stage nanoparticulate carrier system. These 35
observations were confirmed by the results shown in FIG.
21, Panel a and Panel c, in which Carboxyl Q-dots, which
had a negative surface charge (zeta potential —32.8 mV), and
PEG-FITC-SWNTs, with a negative surface charge (zeta
potential —9.21 mV) could be more efficiently loaded into 40
LP APTES modified silicon particles, than into the LP
oxidized silicon particles, which had a negative surface
charge. Given the wide range of protocols available to
modify porous silicon',21-35, it is possible to efficiently load
any kind of second stage particles by exploiting first and 45
second stage surface chemistries.
Loading of second stage nanoparticles was a very rapid
process. FIG. 21, Panels a and c illustrate the results
obtained when LP oxidized silicon particles and LP APTES
modified silicon particles were incubated with a fixed 50
amount of both Amino and Carboxyl Q-dots and PEG-FITC-
SWNTs. Complete loading of the first stage porous silicon
particles occurred within 15 min if the combination of first
stage porous silicon particles and second stage particles
matched the electrostatic criteria described above. The load- 55
ing of SP oxidized silicon particles and SP APTES modified
silicon particles with second stage nanoparticles was also
evaluated (FIG. 21, Panels c and d, respectively). Q-dots
size was between 13 and 16 mu so they could not be loaded
into the pores of SP silicon particles (5-7 mu). On the 60
contrary, the pores of LP silicon particles (20-40 mu) were
sufficiently large to allow Q-dots loading. As a consequence,
SP particle mean fluorescence was only 6% of LP particles.
Conversely, the smaller size of the PEG-FITC-SWNTs was
compatible with SP particle pores, resulting in increased 65
loading (25% of the PEG-FITC-SWNTs loaded into the LP
silicon particles).
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Releasing Second Stage Nanoparticles from First Stage
Silicon Particles
To evaluate the multistage delivery system as a tool for
drug delivery, the kinetics of release of the second stage
particles from the nanoporous silicon first stage particles
was investigated. In order to mimic physiologic conditions,
all the experiments were performed at 37° C. in buffered
saline and the release solution was replaced at each time
point. FIG. 21, Panels e-h, demonstrate that both types of
second stage particles were released over time from the first
stage silicon particles. Surprisingly, the release process was
sustained, with complete release reached after 20 hours. In
addition, the release kinetics significantly differed between
Q-dots and PEG-FITC-SWNTs, with Q-dots being released
significantly faster than SWNTs.
Control experiments performed with SP oxidized silicon
particles (FIG. 21, Panel f) and SP APTES modified silicon
particles (FIG. 21, Panel h) confirmed that Q-dots were not
loaded inside the pores. Detachment of Q-dots from the
surfaces of SP silicon particles was massive and rapid
(>80% in 15 min) suggesting that they were loosely inter-
acting with the silicon particle surface. In contrast, the
kinetics of release of the PEG-FITC-SWNTs second stage
nanovectors from LP and SP silicon particles were compa-
rable, confirming that PEG-FITC-SWNTs were loaded into
the pores of first stage SP particles.
Confocal microscopy was used to further characterize
loading of the second stage nanoparticles into the pores of
the silicon carriers. FIG. 22, Panels a-b, show a series of 3
dimensional projections and rotations of LP APTES silicon
particles loaded with Carboxyl Q-dots. A more intense
fluorescence signal was detected in the central region of the
back face of the silicon particles, where larger pores are, see
FIG. 19, Panel a. The less intense signal coming from the
surrounding areas was due either to partial loading into
smaller pores or by the interaction of Q-dots with the surface
of the silicon particle.
Multiple Loading
Both red fluorescent Q-dots (emission 565 mu) and green
fluorescent PEG-FITC-SWNTs, (emission 510 mu) were
simultaneously loaded into the same nanoporous silicon
particles (FIG. 23A, Panels A and B). These studies dem-
onstrated that both types of second stage particles could be
loaded into the same nanoporous silicon particle carriers.
The dynamics of multiple loading were different from the
ones described for single loading and reached a stable
plateau after 60 minutes. The PEG-FITC-SWNTs were the
first to lodge inside the pores probably as a result of their
smaller size, while larger Q-dots took more time but reached
a higher level of loading (FIG. 23B, Panel Q. The release
profiles of both types of second stage particles from the
silicon carrier remained almost unaltered (FIG. 23B, Panel
D) compared to the observations of release, shown in FIG.
21 Panel B. Confocal microscopy images shown in FIG.
23C, Panels E-H, demonstrate that the two different second
stage nanovectors preferentially localized to different areas
of the silicon particle. Given their larger size, Q-dots were
exclusively found in the central area in association with
larger pores. PEG-FITC-SWNTs were found around the
whole particle, with primary accumulation along the borders
of the particle, in association with smaller pores.
When loaded silicon particles were incubated with
HUVEC cells for 1 h at 37° C., second stage particles were
released locally and selectively internalized by the cells that
were reached by the first stage particles. Q-dots (FIG. 24,
Panels a-d) and PEG-FITC-SWNTs (FIG. 24, Panels e-h)
entered the cytosol of the cells and resulted in significant
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accumulation inside cytoplasmic vesicles. It was next
attempted to deliver both nanoparticles after having loaded
them into the first stage silicon particle. Internalization of
both nanoparticles occurred with similar kinetics and
through the same mechanisms as suggested by the co-
localization of the fluorescent signals (FIG. 24, Panels j-m).
In all cases, the 3.5 µm silicon particles on their own were
not internalized by the cells within the 1 h period. The bright
field images in FIG. 24 Panels d, h and m show the details
of particle morphology suggesting that they were associated
with the external cell surface rather than internalized by the
cell, which was also verified by confocal imaging.
Discussion
Silicon is widely used in the microelectronics industry,
and has demonstrated its capacity for mass production of
microchips as well as for the development of biosensors,
implantable devices, and drug delivery systems36-39 While
bulk silicon remains inert in physiological buffer, porous
silicon has a high degree of biodegradability with degrada-
tion kinetics that may be finely tuned between hours to days
according to pore size density41,41 Porous silicon particles
degrades to silicic acid, which is harmless to the body and
we have found that neither whole intact silicon particles nor
their degradation products are cytotoxic for cells. The fab-
rication protocols may allow the manufacturing of silicon
particulates of any desired shape, size (dimensions from 100
nm to hundreds of µm), pore size (5-100 mu), and/or pore
density.
In addition, protocols to chemically modify the particles,
as attaching PEG to the surface of silicon particles in order
to reduce plasma protein adsorption, RES uptake, and to
increases the circulation time of the particle as a drug
delivery systems42 (manuscript in preparation) have been
developed. Successful conjugation of silicon particles to
specific antibodies directed against ligands of therapeutic
importance such as vascular endothelial growth factor recep-
tor 2 (VEGFR2) and epidermal growth factor receptor
(EGFR) and have evaluated their targeting and selective
cytotoxicity using an in-vitro cell culture model of primary
HUVEC, as described above in Working Example 1.
The present studies provide evidence of the ability of
efficient loading of nanoporous silicon particles with second
stage nanoparticles of different natures, sizes, and shapes.
The loading process may be regulated by adjustment of the
concentration of nanoparticles and/or by taking advantage of
the chemical surface properties of either or both first and
second stage particles. The dynamics of nanoparticle release
and explored the ability of the nanoporous silicon particles
to be loaded with multiple types of nanoparticles simulta-
neously has been shown in the present studies. These studies
have clearly demonstrated that the Q-dots and PEG-FITC-
SWNTs used as second stage particles may localize to
different compartments of the first stage silicon nanoporous
particle carriers according to the size and chemical proper-
ties of the second stage particles. Furthermore, the key
mechanisms and the driving forces that are responsible for
the loading and release processes have been identified and
ranked. The relative size of the pores of the silicon particles
and of the second stage particles together may determine the
most successful configuration of the combination of first and
second stage particles (FIG. 25, Panel A). Concentration of
the second stage nanovectors influences the efficiency of the
loading process, which may be regulated both by passive
diffusion and capillary convection of the second stage par-
ticles into the nanopores of the silicon particles. Hydrody-
namic interactions of the second stage nanovectors with the
nanopores of the silicon particles and Brownian motion
42
affects stability of the assembled system and the time that the
second stage nanovectors remain loaded inside the nanop-
ores of the first stage silicon particles (FIG. 25, Panel B).
Finally, a third mechanism that may be considered is the
5 electrostatic interaction between the first stage silicon par-
ticle carrier and the second stage nanovectors (FIG. 25,
Panel C). Taken together, each of these features may allow
the fine tuning of the amount of second stage nanovectors
that may be loaded into the first stage nanoporous silicon
10 particles, which may be matched to a specific pharmaco-
logical need in future applications of drug delivery.
The original and unique properties of the multi-stage
nanocarrier system may allow multiple therapeutic agents,
penetration enhancers or imaging contrast agents to be
15 delivered for the simultaneous detection and then destruc-
tion of tumors or for imaging and then treatment of other
pathological conditions.
METHODS
20
Fabrication of Porous Silicon Particles
A heavily doped p++ type Si(100) wafer with a resistivity
of 0.005 ohm cm-1 (Silicon
Quest International, Santa Clara, Calif., USA) was used as
25 the substrate. A 200 mu layer of silicon nitride was deposited
by low-pressure chemical vapor deposition (LPCVD) sys-
tem. Standard photolithography was used to pattern using a
contact aligner (EVG 620 aligner). Silicon particles of small
diameter (100-500 mu) were obtained by flash imprint
30 lithography. The nitride was then selectively removed by
reactive ion etching (RIE). The photoresist was removed
with piranha (H2SO4:H2O2 3:1 (v/v)). The wafer was then
placed in a home-make Teflon cell for electrochemical
etching. The silicon particles with large pores (LP) were
35 formed in a mixture of hydrofluoric acid (49% HE) and
ethanol (3:7 v/v) by applying a current density of 80 mA
CM-2 for 25 s. A high porosity layer was formed by applying
a current density of 320 mA cm2 for 6 s. For fabrication of
silicon particles with small pores (SP), a solution of HE and
40 ethanol was used with a ratio of 1:1 (v/v), with a current
density applied of 6 mAcrri 2 for 1.75 min. The high porosity
layers were formed by applying a current density of 320 mA
CM-2 for 6 s in an HF:ethanol mixture with a ratio of 2:5
(v/v). After removing the nitride layer by HF, particles were
45 released by ultrasound in isopropyl alcohol (IPA) for 1 min.
The IPA solution containing porous silicon particles was
collected and stored at 4° C.
BET Measurement
The nitrogen adsorption desorption volumetric isotherms
50 obtained at 77 K were measured on a Quantachrome
Autosorb-3b BET Surface Analyzer. The samples were
baked at 150° C. in vacuum overnight. Particle surface area
was obtained by BET linearization in the pressure range 0.05
to 1 P/P0. For the LP particles, the BET surface area was 156
55 m2 g-'  and pore volume was 0.54 cm3 g-1 using nitrogen
adsorption-desorption isotherm measurements. The average
pore size was estimated to be about 24.2 mu. For SP
particles, the BET surface area was measured 294 m2 g-1;
pore volume was 0.38 cm3 g-'  and the average pore size was
60 7.4 mu.
Analysis of Particle Size and Concentration in Solution
Particles were counted using a Z2 Coulter® Particle
Counter and Size Analyzer (Beckman Coulter, Fullerton,
Calif., USA), with a 50 µm aperture size. The upper and
65 lower size limits for analysis were set at 1.8 and 3.6 µm. For
analysis, particles were suspended in the balanced electro-
lyte solution (ISOTON® II Diluent, Beckman Coulter Ful-
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lerton, Calif., USA) and counted. The total volume of
original suspension of particles did not exceed 0.3% of the
final analysis volume. The particle counter displays the
concentration of particles in the solution as well an analysis
of the particle size distribution.
Oxidation of Silicon Microparticles
Silicon microparticles in IPA were dried in a glass beaker
by heating (80-90° C.) and then oxidized them in a piranha
solution (1:2 H202: concentrated H2SO4 (v/v)). The particles
were added to a solution of H2O2 (30%), sonicated in a
551OR-MT ultrasonic cleaner (BRANSONIC, Danbury, CT,
USA) for 30 s and then H2SO4 (95-98%) was added and the
suspension was heated to 100-110° C. for 2 h, with inter-
mittent sonication to disperse the particles. The particles
were then washed with deionized (DI) water. Washing of the
particles in DI water involves centrifugation of the particu-
late suspension at 4,200 rpm for 5 min followed by removal
of the supernatant and resuspension of the particles in DI
water. The oxidized silicon particles were stored at 4° C. in
DI water until further use.
Surface Modification of Silicon Particles with 3-Aminopro-
pyltriethoxysilane (APTES)
Prior to silanization, the oxidized silicon particles were
hydroxylated in 1.5 M HNO3 for approximately 1.5 h. The
particles were then washed 3-5 times with DI water followed
by 2 washes with IPA. The silicon particles were then
suspended in IPA containing 0.5% (v/v) APTES for 45 min
at room temperature. The particles were then washed with
IPA (4,200 g for 5 min, 5 times), and stored in IPA at 4° C.
Q-dots and Water Fluorescently Labeled Water-Soluble
SWNTs.
Q-dots were purchased from Invitrogen (Carlsbad, Calif.,
USA). In this study, we used Amino-PEG with 525 nm and
565 nm emission wavelength (catalogue number
Q2154IMP and Q2153IMP respectively) and Carboxyl
Q-dots with 525 nm and 565 nm emission wavelength
(catalogue number Q2134IMP and Q2133IMP respec-
tively). To produce ultra-short (US)-SWNTs 43 that are
heavily sidewall carboxylated, oleum (20% free SO3, 25
mL) was added to purified HiPco SWNTs (0.100 g) under
nitrogen in round bottom flask and the mixture was stirred
overnight to disperse the SWNTs (HiPco SWNTs were
obtained from the Rice University HiPco laboratory. For the
purification established procedures were followed.44 In a
separate flask, oleum (25 mL, 20% free SO3) was slowly
added to concentrated nitric acid (18 mL). This mixture was
immediately added to the SWNTs and the SWNTs were
heated to 60° C. for 2 h. The solution was then slowly poured
over ice and filtered over a 0.22 µm polycarbonate mem-
brane. The filter cake was thoroughly washed with water.
The vacuum was removed and the cake was dissolved in a
minimal amount of methanol after which ether was added
leading to flocculation of the US-SWNTs and the vacuum
was reapplied. Ether was continually added until a neutral
pH was achieved from the washings. The US-SWNT cake
was dried under vacuum. To obtain PEGylated SWNTs,
US-SWNTs (0.034 g, 3.1 meq C) were dispersed in dry
DMF (30 mL) using sonication (bath or cup-horn, and
Model) for 30 min in a round bottom flask. To this, Dicy-
clohexylcarbodiimide (DCC) (0.32 g, 1.5 mmol), and 5,200
MW of hydroxyethyl phthalimide terminated PEG (0.32 g)
were added and the mixture stirred under nitrogen for 24 h.
The solution was transferred to a dialysis bag (CelluSep Hl,
50,000 MWCO, Part #: 1-5050-34, Membrane Filtration
Products) for 5 d and the product filtered through glass wool
to remove any particulate that formed in the dialysis bag.
The contents of the dialysis bag were subjected to removal
Ir!
of the phthalimide moiety revealing the PEG-terminated
amine (H2H-PEG-US-SWNT). Hydrazine monohydrate (10
mL) was added to and the solution was heated to reflux
under nitrogen for 12 h to give a terminal primary amine on
5 the end of the PEGylated US-SWNT. The product was
purified by dialysis in DI water for 5 days. The solution was
then transferred to a round bottom flask wrapped in foil and
FITC (0.12 g) predissolved in a small amount of DMF was
added to the H2H-PEG-US-SWNT solution. The reaction
io was stirred at room temperature for 12 h. The solution was
transferred to a dialysis bag and was kept in continuous
dialysis with DI water in the dark for 5 days followed by
filtration through glass wool to remove the undissolved
particulates. The final product FITC-PEG-US-SWNT con-
15 tained some FITC physisorbed to the PEG-US-SWNTs
instead of being covalently attached. Most of the phy-
sisorbed FITC still remains associated with the SWNTs after
months of dialysis in water.
Measurement of Zeta Potential of Silicon Particles, Q-dots,
20 and SWNTs
The zeta potential of the silicon particles, Q-dots, and
FITC-PEG-US-SWNTs were analyzed using a Zetasizer
nano ZS (Malvern Instruments Ltd., Southborough, Mass.,
USA). The particles were suspended in 20 mM Tris(hy-
25 droxymethyl)aminomethane (TRIS-HCL) buffer (pH 7.3)
for the analysis.
Loading of Q-dots and SWNTs Into First Stage Silicon
Particles
The silicon nanoporous particles that were used in devel-
30 opment of the multi-stage nanodevice include LP oxidized
porous silicon, SP oxidized porous silicon and APTES
modified LP and SP particles. The second stage particles
include Amino-PEG Q-dots, Carboxyl Q-dots, and PEG-
FITC-SWNTs. Initial experiments were performed to titrate
35 the loading of the second stage particles into the first stage
silicon particles. For each experimental point of the titration
experiments, 3.0x105 silicon particles were used, which
were resuspended in low binding polypropylene micro cen-
trifuge tubes (VWR International, West Chester, Pa., USA)
40 containing 3µl DI water. For every experiment, the given
molarity of TRIS-HCl solution was adjusted at pH 7.3.
Either 2µM Q-dots (5 µl) or 20 ng/µl PEG-FITC-SWNTs (9
µl) were added to the TRIS-HCl solution, with 20 µl as the
final volume for the loading experiments. Samples were
45 incubated by being placed on a rotating wheel (20 rpm) for
15 min at 25° C. After incubation, the samples were diluted
with 20 mM TRIS-HCl, pH 7.3 to a volume of 150 µl and
promptly examined for fluorescence intensity using a FAC-
Scalibur (Becton Dickinson) flow cytometer. To evaluate the
50 concentration dependent loading of Q-dots and PEG-FITC-
SWNTs into silicon particles, we used 3.0x105 silicon
particles and an incubation time of 15 min, with either 0.01,
0. 1, 1, 10, 100, 1,000 and 2,000 nM Q-dots or 0.05, 0,1, 2.5,
10 and 20 ng/µl of PEG-FITC-SWNTs. To evaluate the time
55 dependent loading, 3.0x105 first stage particles, 2,000 nM
Q-dots or 20 ng/µl of PEG-FITC-SWNTs with incubation
times of 15, 30, 45 and 60 minutes were used. For evaluation
of loading of silicon particles with both Q-dots and PEG-
FITC-SWNTs, 3.0x105 silicon particles, 1,000 nM Q-dots,
6o and 10 ng/µl of PEG-FITC-SWNTs were used with the same
final volume of incubation.
Studies of release of Q-dots and SWNTs from first stage
silicon particles.
LP silicon particles (2.1 x 106), which were either oxidized
65 or APTES modified, were combined with 2µM Amino-PEG
Q-dots or Carboxyl Q-dots in a 200 mM TRIS-HCl solution
at pH 7.3 or with 20 ng/µl PEG-FITC-SWNTs in a 20 mM
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TRIS-HC1 solution at pH 7.3 or with both 1µM Q-dots and
10 ng/µl PEG-FITC-SWNTs in a 50 mM TRIS-HCl solution
at pH 7.3. The final incubation volume for all studies was
140 µl. Samples of first stage silicon particle carriers and
second stage particles were incubated using a rotating wheel
(20 rpm) for 15 min at 25° C. The solution containing the
first stage silicon particles and second stage particles were
then washed in 1.4 mL DI H2O, and then centrifuged for 5
min at 4,200 rpm in a Beckman Coulter Allegra X-22
centrifuge. Pellets present after centrifugation were then
resuspended in 70 µl of DI H2O and 10µl was removed from
each vial to assess the fluorescence of the samples using flow
cytometry. Fluorescence was recorded at time 0 and then
over 6 time points, which included 30, 60, 90, 180, 360, and
1,200 min. The residual 60 µl left in each vial was diluted to
3 ml in 20 mM TRIS-HCl 0.9% NaCl release buffer,
followed by incubation using a rotating wheel (20 rpm) for
the given amount of time (30, 60, 90, 180, 360 and 1,200
min) at 37° C. At each time point, samples were centrifuged
for 5 min at 4,200 rpm and the fluorescence evaluated using
flow cytometry.
Flow Cytometry Setup
Particles were assessed for fluorescence using a FAC-
Scalibur (Becton Dickinson). Bivariate dot-plots defining
logarithmic side scatter (SSC) versus logarithmic forward
scatter (FSC) were used to evaluate the size and shape of the
silicon particles (3 µm in diameter, 1.5 µm in height) and to
exclude non-specific events from the analysis. Control rain-
bow BD CalibriteTM beads (3.5 µm in size) were used to
calibrate the instrument. A polygonal region (RI) was
defined as an electronic gate around the centre of the major
population of interest, which excluded events that were too
close to the signal-to-noise ratio limits of the cytometer. For
each sample, the number of particles detected within the RI
region was above 90%. For analysis of the geometric mean
fluorescence intensity (GMFI), dot-plots were created which
compared fluorescence channel 1 (FLI) and FL2 versus log
FSC with analysis of events falling within the gated region
defined as RL The peaks identified in each of the samples
were analyzed in the corresponding fluorescent histogram
and the geometric mean values recorded. For particle detec-
tion, the detectors used were FSC E-1 and SSC with a
voltage setting of 474 volts (V). The fluorescent detector
FLl was set at 800 V. Green fluorescence (FITC and Q-dots
525) was detected with FL1 using a 530/30 nm band-pass
filter. Red fluorescence (Q-dots 565) was detected using
FL2. When single color detection only was analyzed, color
compensation was set at zero, and when dual red-green color
detection was performed, FL  compensation was set at 25%
of FL2 and FL2 compensation was set at 35% of FLl.
Instrument calibration was carried out before, in between,
and after each series of experiments for data acquisition
using BD CalibriteTM beads.
Scanning Electron Microscopy
The morphology of the silica particles was acquired using
scanning electron microscopy (SEM, model LEO 1530). Par-
ticles were directly placed on SEM samples stage and dried.
For the particles tested in the high salt buffers, a mild
washing step in DI water was performed before putting on
the stage. The acceleration voltage was 10 kV.
Tapping Mode Atomic Force Microscopy (AFM)
AFM samples were prepared by deposition from DMF
onto a freshly cleaved mica surface. Samples were spin
coated and sectional analysis was used to determine the
heights of each sample. AFM samples were obtained using
tapping mode.
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Bright Field Microscopy
Particles were analyzed in bright field contrast with an
Olympus CKX41 microscope with a 40x magnification lens.
Images were taken with an SP-350 Olympus True-Pic
5 TURBO Image Processor camera.
Fluorescent Microscopy
Fluorescent imaging of particles was performed with a
Nikon Eclipse TE2000-E with a DQC-FS Nikon CCD
Camera kept at —30.1' C. All the samples were mounted
10 immediately before the analysis and the images acquired
with a 63x immersion oil objective. The microscope settings
were kept constant throughout all the experiments. numeri-
cal aperture was set at 1.4, refractive index at 1.515, expo-
15 sure time at 500 ms, readout Speed at 10 MHz and conver-
sion gain at 1/6x.
The images were analyzed and measured with the NIS
Elements AR 2.3 Software.
Confocal Microscopy
20 Confocal imaging of particles was performed with a
LEICA DM6000 microscope. All the samples were mounted
immediately before the analysis and the images acquired
with a HCX PL APO CS 63x immersion oil objective with
a 1.4 numerical aperture and 1.52 refraction index. For all
25 the acquisitions, the pinhole was set at 95.6µm (1 Airy unit),
both 488 nm argon and 561 mn lasers were at 15% of their
capacity; the scan speed was set at 400 Hz. The single green
fluorescence imaging photomultiplier voltage was set at 750
V. For dual color imaging, the PMT for the red channel was
30 set at 600 V while the PMT for the green channel was set at
1000 V. To improve the image quality, 2-frame accumula-
tion, 2-line accumulations and 4-frame averages were per-
formed during acquisitions. Final voxel width and height
were 19.8 mu. The images were magnified digitally (10x)
35 and a median adjustment (3 pixels, 2 rounds) was used
during the post-processing using the LAS AF 1.6.2 software.
WORKING EXAMPLE 3
4o Liposomes in 3.5 Micron Silicon Particles
Fluorescently labeled siRNA loaded 1,2-dioleoyl-sn-
glycero-3-phosphaticholine (DOPC) liposomes were pre-
pared as detailed in C. N. Landen Jr., et al. Cancer Res. 2005,
65(15), 6910-6918, and J. Clin. Cancer Res. 2006; 12(16),
45 4916-4924.
Fluorescently labeled siRNA loaded DOPC liposomes
(original siRNA concentration: 100 ng/µl), as second stage
particles, were mixed with 1 st stage large pore "LP" oxi-
dized silicon particles (3.5 micron). Incubation was per-
50 formed in 20 mM Tris pH 7.3 for 30 min at room tempera-
ture. The solution was spun down at 4,200 rpm for 1 min at
room temperature. The supernatant was recovered and the
fluorescence of the sample was measured by fluorimetry
using 544 nm/590 mn (excitation/emission) settings. The
55 particle pellet comprising the 1 st stage particles that had
incorporated the fluorescent liposomes were resuspended in
100 µl of deionized water and fluorimetric readings were
taken. The loading time dynamics of Fluorescently labeled
siRNA loaded DOPC liposomes into 3.5 micron LP and SP
60 particles is shown in FIG. 813, Panel D. In FIG. 813, Panels
E and F show fluorescent microscopy images visualizing
second stage liposomes containing Alexa 555 labeled
SiRNA into 3.5 micron nanoporous silicon first stage par-
ticles LP in white field and red field respectively
65 Alexa 555 fluorescently labeled siRNAs were encapsu-
lated into liposomes and loaded into the 1st stage porous
silicon particles. The data in FIG. 26, Panel A, show that the
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fluorescence associated with the porous Silicon carrier
increased with the amount of nanoliposomes.
To test the release of liposome from 1 st stage particles, the
assembled multistage systems were incubated with 10%
fetal bovine serum (pH 7.4) and release of nanoliposomes
from the 1 st stage particles was followed along time using
fluorimetry. Complete unloading was achieved in about 36
h, see FIG. 26, Panel B.
WORKING EXAMPLE 4 10
Liposomes to Silicon Particles
Preparation of Liposomes:
Liposomes with a lipid composition of 58:40:2 (Mol %)
DPPC: Cholesterol: DSPE-Methoxy PEG (2000) respec- 15
tively may be made by the extrusion process as follows:
Briefly, the lipids may be dissolved in ethanol at 55 oC. The
dissolved lipids may then be hydrated with 300 mM ammo-
nium sulfate solution (for 15-30 minutes) to facilitate active
loading of doxorubicin, see Li, et al. Biochim et Biophys 20
Acta 1415 (1998). Liposomes may be extruded through a
series of Nuclepore track-etched polycarbonate membranes
of decreasing pore sizes. The liposomes may then be
extruded 5 times through a 0.2 µm membrane. This may be
followed by an extrusion through 0.1 µm membrane (5 25
times), then through a 0.05 µm membrane (5 times). The
final extrusion may be through a 0.03 µm membrane (10
times). The extrusions may be carried out at 55 oC.
Produced fluorescently labeled liposomes contained 30%
of DiPalmitoylPhosphatidylCholine(DPPC) lipids, 30% of 30
cholesterol, 10% of fluorescently labeled lipid N-[7-ni-
trobenz-2-oxa-1,3-diazol-4-yl] dipalmitoyl-L-a-phosphati-
dylethanolamine (NBD-PE) lipid mixed with either 30%
1,2-Dioleyl-3-trymethylammoniumpropane (DOTAP) (for
cationic liposomes), or 30% dioleoylphosphatidyl glycerol 35
(DOPG) (for anionic liposomes), or 30% dioleoylphospha-
tidyl choline DOPC (for neutral liposomes).
Neutral liposomes had initial mean diameter 47.4 mn and
mean diameter after 3 days 78.2 nm as determined by
Dynamic Light Scattering (DLS). Zeta potential of neutral 40
liposomes was -13.04±0.77 mV.
Cationic liposomes had initial mean diameter 49.6 nm and
mean diameter after 3 days 58.2 mn as determined by DLS.
Zeta potential of cationic liposomes was 30.30±2.55 mV.
Neutral and cationic liposomes were loaded in 1 micron 45
"large pore" (LP) oxidized nanoporous silicon particles and
1 micron "large pore" (XLP) oxidized and APTES modified
silicon particles. FIG. 8A, Panel A, shows confocal micros-
copy images of neutral (left) and cationic (right) fluores-
cently labeled liposomes loaded into 1 micron XLP APTES 50
modified silicon particles. FIG. 8A, Panel B, shows FACS
analysis for neutral and cationic fluorescently labeled lipo-
somes loaded into 1 micron XLP oxidized and APTES
modified silicon particles and 1 micron LP oxidized par-
ticles. FIG. 8A, Panel C shows Excel quantification of 55
fluorescently labeled liposome loading.
Loading of Doxorubicin as an Active Agent:
The liposomes may be dialyzed overnight against 150
mM NaCl to remove unencapsulated ammonium sulfate to
generate a trans-membrane proton gradient. Doxorubicin 60
(-10 mg/ml) may be added to the liposomes at 60° C. for 1
hr. The drug:lipid ratio will be 0.2:1.0 and the final lipid
concentration will be -25 mM. The resulting liposomal
formulation may be kept on ice for 15 minutes to stop the
remote loading process. The liposomes may be dialyzed 65
overnight against 150 mM NaCl to remove unencapsulated
doxorubicin. The final encapsulated Doxorubicin concentra-
48
tion may be determined by lysis with methanol (30% of final
volume) and measuring the UV absorbance at 480 nm.
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60 Although the foregoing refers to particular preferred
embodiments, it will be understood that the present inven-
tion is not so limited. It will occur to those of ordinary skill
in the art in light of this disclosure that various modifications
may be made to the disclosed embodiments and that such
65 modifications are intended to be within the scope of the
present invention. All of the publications, patent applications
and patents cited in this specification are incorporated herein
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by reference to the extent that they provide details and
description consistent with and supplemental to this disclo-
sure.
The invention claimed is:
1. A multistage delivery composition comprising:
a first stage particle containing second stage particle,
wherein the first stage particle, comprises:
(i) a body;
(ii) at least one surface with a surface charge; and
(iii) a plurality of nanoscale reservoirs in the body of the
first stage particle,
wherein each reservoir is connected to at least one surface
of the body through at least one channel,
wherein the at least one channel is in the form of a pore
open to the surface,
wherein at least one of the plurality of the nanoscale
reservoirs contains the second stage particle in the pore
open to the surface, and wherein:
the first stage particle is biodegradable and has a selected
non-spherical shape;
the first stage particle is a porous micro or nanoparticle
with a size from about 100 mn to about 5 microns;
the second stage particle encapsulates a therapeutic agent;
the first stage particle is configured to overcome a first
biological barrier; and
the second stage particle is configured to overcome a
second biological barrier, wherein the first stage par-
ticle and the second stage particle are configured to
sequentially overcome the first biological barrier and
second biological barrier respectively.
2. The multistage delivery composition of claim 1
wherein the first stage particle is configured to release the
second stage particle for delivery of the therapeutic agent.
3. The multistage delivery composition of claim 1
wherein the first stage particle is configured to release the
second stage particle for delivery of the therapeutic agent via
diffusion of the second stage particle through the channels in
the first stage particle.
4. The multistage delivery composition of claim 1
wherein the first stage particle is configured to release the
second stage particle for delivery of the therapeutic agent via
degradation or erosion of the body the first stage particle.
5. The multistage delivery composition of claim 1
wherein the first biological barrier and the second biological
barrier are each independently selected from the group of
biological barriers consisting of a hemo-rheology barrier, a
reticulo-endothelial system barrier, an endothelial barrier, a
blood brain barrier, a tumor-associated osmotic interstitial
pressure barrier, an ionic and molecular pump barrier, a cell
membrane barrier, an enzymatic degradation barrier, a
nuclear membrane barrier, and any combination of thereof.
6. The multistage delivery composition of claim 1
wherein the first stage particle comprises a chemical target-
ing moiety disposed on the surface of the first stage particle,
wherein said chemical targeting moiety comprises at least
one moiety selected from the group consisting of dendrimer,
an aptamer, an antibody, a biomolecule and any combination
thereof.
7. The multistage delivery composition of claim 1
wherein at least one of the plurality of nanoscale reservoirs
contains at least one additional agent.
8. The composition of claim 7, wherein the at least one
additional agent comprises at least one penetration enhancer,
at least one additional active agent, or at least one targeting
moiety.
9. The composition of claim 8, wherein the at least one
penetration enhancer is selected from the group consisting of
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a basement membrane permeation enhancer, a tight junction
protein (tjp) permeation enhancer and any combination
thereof.
10. The composition of claim 1, wherein the first stage
5 particle is configured to release the second stage particle in
response to an external stimulus.
11. A method comprising administering to a subject a
composition comprising:
a first stage particle containing a second stage particle,
to 
wherein the first stage particle comprises:
(i) a body;
(ii) at least one surface with a surface charge; and
(iii) a plurality of nanoscale reservoirs in the body of the
15 first stage particle,
wherein each reservoir is connected to at least one surface
of the body through at least one channel,
wherein the at least one channel is in the form of a pore
open to the surface,
20 wherein at least one of the plurality of the nanoscale
reservoirs contains the second stage particle in the pore
open to the surface, and wherein:
the first stage particle is biodegradable and has a selected
non-spherical shape;
25 the first stage particle is a porous micro or nanoparticle
with a size from about 100 mn to about 5 microns;
the second stage particle encapsulates a therapeutic agent;
the first stage particle is configured to overcome a first
biological barrier; and the second stage particle is
so configured to overcome a second biological barrier,
wherein the first stage particle and the second stage
particle are configured to sequentially overcome the
first biological barrier and second biological barrier
respectively.
35 12. The method of claim 11 wherein the first stage particle
is configured to release the second stage particle for delivery
of the therapeutic agent.
13. The method of claim 11 wherein the first biological
barrier and the second biological barrier are each indepen-
4o dently selected from the group of biological barriers con-
sisting of a hemo-rheology barrier, a reticulo-endothelial
system barrier, an endothelial barrier, a blood brain barrier,
a tumor-associated osmotic interstitial pressure barrier, an
ionic and molecular pump barrier, a cell membrane barrier,
45 an enzymatic degradation barrier, a nuclear membrane bar-
rier, and any combination of thereof.
14. The method of claim 11 wherein the first stage particle
comprises a chemical targeting moiety disposed on the
surface of the first stage particle, wherein said chemical
50 targeting moiety comprises at least one moiety selected from
the group consisting of dendrimer, an aptamer, an antibody,
a biomolecule and any combination thereof.
15. The method of claim 11 wherein the at least one of the
plurality of nanoscale reservoirs contains at least one addi-
55 tional agent.
16. The method of claim 11 wherein the at least one
additional agent comprises at least one penetration enhancer,
at least one additional active agent, or at least one targeting
moiety.
60 17. The method of claim 11 wherein the composition is
administered intravascularly.
18. A method of fabricating a multistage delivery com-
position, comprising:
(a) providing a first stage particle, wherein the first stage
65 particle comprises:
(i) a body;
(ii) at least one surface with a surface charge; and
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(iii) a plurality of nanoscale reservoirs in the body of the
first stage particle,
wherein each reservoir is connected to at least one
surface of the body through at least one channel,
wherein the at least one channel is in the form of a pore
open to the surface, and wherein:
the first stage particle is biodegradable and has a selected
non-spherical shape;
the first stage particle is a porous micro or nanoparticle
with a size from about 100 mn to about 5 microns;
(b) providing a second stage particle;
and
(c) loading the second stage particle inside one of the
plurality of nanoscale reservoirs of the first stage par-
ticle such that the nanoscale reservoir contains the
second stage particle in the pore open to the surface,
and such that the first stage particle is configured to
overcome a first biological barrier and the second stage
particle is configured to overcome a second biological
barrier, wherein the first stage particle and the second
stage particle are configured to sequentially overcome
the first biological barrier and second biological barrier
respectively.
19. The method of claim 18, wherein loading the second
stage particle inside one of the plurality of nanoscale reser-
voirs of the first stage particle comprises placing the first
stage particle and the second stage particle in a sealed
chamber having a pressure above atmospheric pressure.
20. The method of claim 19 wherein first stage particle
and the second stage particle are submerged in a solution in
the sealed chamber.
21. The method of claim 20 wherein the first stage particle
is subjected to reduced pressure prior to being placed in the
solution in the sealed chamber.
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22. The of method claim 18, wherein loading the second
stage particle inside one of the plurality of nanoscale reser-
voirs of the first stage particle comprises loading via passive
diffusion or capillary convection, or by a combination of
5 those.
23. The method of claim 18 wherein loading the second
stage particle inside one of the plurality of nanoscale reser-
voirs of the first stage particle comprises modifying a
surface charge of the first particle or the second particle.
10 24. The multistage delivery composition of claim 1,
wherein the second stage particle comprises a plurality of
second stage particles stacked within the pore open to the
surface.
25. The method of claim 11, wherein the second stage
15 particle comprises a plurality of second stage particles
stacked within the pore open to the surface.
26. The method of claim 18, wherein the second stage
particle comprises a plurality of second stage particles
stacked within the pore open to the surface.
20 27. The multistage delivery composition of claim 1,
wherein the second stage particle comprises at least one
constituent selected from the group consisting of a liposome,
a micelle, an ethosome, a carbon nanotube, a fullerene
nanoparticle, a metal nanoparticle, a semiconductor nano-
25 particle, a polymer nanoparticle, an oxide nanoparticle, a
viral particle, a polyionic particle and a ceramic particle.
28. The method of claim 11, wherein the second stage
particle comprises at least one constituent selected from the
group consisting of a liposome, a micelle, an ethosome, a
30 carbon nanotube, a fullerene nanoparticle, a metal nanopar-
ticle, a semiconductor nanoparticle, a polymer nanoparticle,
an oxide nanoparticle, a viral particle, a polyionic particle
and a ceramic particle.
